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to recommended targets to avoid long- term complica-
tions including blindness, renal failure, amputations 
and premature death.2 In addition, exogenous insulin 
therapy can prevent high blood glucose and acute, life- 
threatening emergencies such as diabetic ketoacidosis, as 
well as being a tool to prevent long- term complications.
Achieving the blood glucose control to help prevent 
complications depends on an individual’s ability to self- 
manage their condition, calculating precise insulin doses 
based on accurate estimations of food intake before every 
meal, frequent blood glucose measurements and account 
for fluctuations in physical activity, illness and hormones. 
If people with T1D are unable or unwilling to calculate 
and administer their insulin doses correctly, their blood 
glucose either runs high, increasing the risks of compli-
cations or else falls too low leading to hypoglycaemia. 
Hypoglycaemia, if severe, can result in acute cognitive 
impairment, confusion, collapse and injury, coma or even 
death.3 Thus, people with T1D must acquire complex 
self- management knowledge and skills, and have the 
motivation and ability to apply them effectively every day. 
The responsibility of diabetes healthcare professionals 
(HCPs) is to ensure that all people with T1D have the 
opportunity to acquire these skills and are supported in 
applying them successfully in everyday life.
‘Dose Adjustment For Normal Eating’ (DAFNE) is a 
structured education programme run within the National 
Health Service (NHS), designed to enable adults with T1D 
to learn or enhance their self- management skills in flexible 
intensive insulin therapy to improve both glucose control 
and quality of life. It is a five- day training course, delivered 
in small groups. DAFNE has been delivered to over 51 000 
adults in the UK.4 The publication of the UK DAFNE 
randomised controlled trial (RCT) in 20025 established the 
ability of structured education courses to enable people with 
diabetes to acquire the knowledge and skills to live success-
fully with this lifelong condition. The subsequent rollout 
of DAFNE across the UK has enabled many individuals to 
meet these demands and achieve their goals, but over half 
of DAFNE graduates still struggle to manage glucose levels 
consistently. After attending a DAFNE course, people have 
better quality of life, better control of blood glucose levels 
and are admitted to hospital less often for diabetes emer-
gencies.6 Many DAFNE graduates find the course helpful; 
quality of life improves and rates of severe hypoglycaemia 
fall. However although glycated haemoglobin (HbA1c) 
falls and in one trial, this improvement was sustained for 2 
years, average HbA1c, the intermediate measure of glucose 
control that best predicts risk of diabetes complications, 
remains well above recommended UK targets.7 8 Many find 
it difficult to implement and sustain the skills needed to 
maintain blood glucose levels and often struggle to obtain 
suitable support from HCPs.6 9–15
The DAFNEplus intervention has been developed 
through modifying the existing DAFNE programme by 
incorporating techniques for initiating and sustaining 
behaviour change, and supplementing this with struc-
tured follow- up support and enhanced information 
technology. The aim of this trial is to investigate whether 
the DAFNEplus programme will produce improved and 
sustainable diabetes self- management behaviour and 
better glucose outcomes than currently achieved with 
standard DAFNE, without compromising quality of life in 
the longer term.
Aims and objectives
The primary aim of this study is to conduct a cluster 
RCT comparing the new DAFNEplus intervention to 
the existing DAFNE programme to answer the following 
question:
In adults with T1D, will modifying the existing 
DAFNE programme and developing structured profes-
sional input, using learning from our recent research, 
behavioural change theory and new forms of technolog-
ical support, produce improved and sustained diabetes 
self- management behaviours, leading to better glucose 
control than currently achieved, using the existing 
DAFNE intervention, without compromising quality of 
life?
The primary objective is to assess the effects of the inter-
vention on glycaemic control, as measured by HbA1c at 
12 months.
The secondary objectives of this trial are:
1. To compare the effects of the intervention (DAFNEplus) 
to standard DAFNE on diabetes- specific quality of life.
2. To compare the medium term effect of the inter-
vention (DAFNEplus) to standard DANFE on glycae-
mic control as measured by HbA1c using data at 6 
months.
3. To compare the effects of the intervention (DAFNE-
plus) to standard DAFNE on other biomedical out-
comes.
4. To compare the effects of the intervention (DAFNE-
plus) to standard DAFNE on psychological outcomes.
5. To undertake a mixed methods process evaluation to 
aid understanding of the RCT findings, and to inform 
decision making about the implementation of DAFNE-
plus in clinical care post- trial.
6. To assess fidelity of delivery of the DAFNEplus inter-
vention.
7. To undertake a health economic analysis to determine 




The study will use a pragmatic cluster RCT design. This 
is required since ‘contamination’ of the control arm may 
occur if DAFNE HCPs, trained in the new programme 
were to deliver standard DAFNE. Hence the randomisa-
tion of DAFNE centres rather than individuals.16 Figure 1 
shows the flow of participants through the trial (see 
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Study setting
The trial will be delivered in adult diabetes centres in 
secondary care NHS hospitals in the UK. The eligibility 
criteria for study centres are:
1. Diabetes centre delivering DAFNE to adults with T1D.
2. At least three DAFNE educators trained in delivering 
the 5- week model of DAFNE.
3. Delivery of sufficient DAFNE courses per year to re-
cruit study sample.
Adults with T1D eligible for or referred to DAFNE 
courses at participating centres as part of usual care 
will be eligible to be invited to participate in the RCT, 
and standard criteria for referral to DAFNE will be 
used.
Figure 1 RCT flow diagram. BMI, body mass index; BP, blood pressure; CSII, continuous subcutaneous insulin infusion; 
DAFNE, dose adjustment for normal eating; EQ- 5D, EuroQoL-5 Dimension 5 Level; HbA1C, glycated haemoglobin; MDI, 























































































































1. Adults (≥18 years).
2. Diagnosis of T1D for at least 6 months, or posthon-
eymoon. The honeymoon period refers to the time 
when, postdiagnosis, people start taking insulin in-
jections, and their insulin producing cells sometimes 
recover temporarily (generally around 3–12 months. 
The dose of insulin needed might reduce during this 
period, and some people might even need to stop us-
ing insulin for a while, but eventually it will be need-
ed again. The criteria for referral to DAFNE at least 6 
months after diagnosis is to allow for the honeymoon 
period to have passed before attendance at the course.
3. Prepared to undertake multiple daily injection thera-
py.
4. Prepared to undertake frequent self- monitoring of 
blood glucose.
5. Confirms availability to attend all sessions as part of the 
intervention.
6. Investigator has confidence that the patient is capable 
of adhering to all the trial protocol requirements.
Exclusion criteria
1. Current use of continuous subcutaneous insulin infu-
sion pump therapy.
2. HbA1c >12% (108 mmol/mol) (Investigators can use 
their judgement, informed by standard DAFNE guide-
lines and in agreement with the trial team, to include 
participants with HbA1c >12%).
3. Serious diabetic complications (eg, blindness, renal di-
alysis). (Investigators can use their clinical judgement, 
informed by standard DAFNE guidelines and in agree-
ment with the trial team).
4. Other serious comorbidities, for example, psychosis, 
diagnosed eating disorder. (Investigators can use their 
clinical judgement, informed by standard DAFNE 
guidelines and in agreement with the trial team).
5. Previous participation in standard DAFNE course less 
than five years before proposed study enrolment date.
6. Unable to speak/hear/understand/read or write in 
English.
7. Unable to give written informed consent.
Recruitment
Patient participants will be identified from current case-
loads of adults with T1D from each participating centre. 
They will be sent an invitation letter and information 
sheet before the course. A member of the clinical team 
in participating centres will then telephone potential 
participants to discuss whether or not they are inter-
ested in principle in taking part. If interested, they will 
be asked to consent to participate at their baseline visit. 
In both trial arms, if they do not want to take part in the 
research they will be offered attendance at a standard 
DAFNE course that is not part of this trial, if that is their 
wish. Reasons for non- participation in the trial will be 
recorded.
In order to maximise recruitment to the courses, a 
reserve list of eligible patients will be held at participating 
centres. Eligible patients may also be invited to take part 
by their HCP during routine face- to- face appointments 
or via telephone. Trial information meetings may also be 
held during the recruitment period at various locations 
in centres.
Written informed consent will be obtained from all 
participants. Members of the local study teams will be 
responsible for taking informed consent from poten-
tially eligible study participants at the DAFNE centres. 
The process for obtaining participant informed consent 
will be in accordance with the REC guidance, and Good 
Clinical Practice (GCP) and any other regulatory require-
ments that might be introduced.
Written informed consent to contribute to the process 
evaluation will also be taken from HCPs in participating 
sites by the central study team.
Interventions
Standard DAFNE (control arm)
DAFNE is a skill- based structured education programme 
for adults with T1D delivered in the NHS. Two evidence- 
based models of delivering standard DAFNE are in opera-
tion, whereby the five sessions of the course are delivered 
weekly or daily, as described elsewhere.17 Each course is 
delivered to seven participants on average (minimum of 
four and maximum of eight). Standard DAFNE will be 
delivered, as usual care, by trained DAFNE educators in 
the NHS, including diabetes specialist nurses, dietitians 
and physicians.
The aim of the course is to train adults with T1D in 
the skills to manage their condition effectively. It covers 
numerous topics in a progressive modular based struc-
ture. In addition to the five days of the course, partici-
pants are asked to attend a baseline appointment before 
the DAFNE course, and they are also typically invited to 
attend an optional group follow- up session 6–8 weeks 
after the course. They may also attend routine appoint-
ments every 6–12 months and seek ad hoc support from 
local diabetes clinicians post- course.
For the purposes of this study, the control arm will 
be the 5- week model of standard DAFNE to match the 
frequency of sessions offered in DAFNEplus. All partici-
pants in the control arm will be given access to a stand- 
alone bolus calculator to assist them with calculating 
insulin doses. There will be no structured follow- up 
appointments beyond those provided in usual care. To 
qualify as adherent for statistical purposes, participants 
need to have attended the equivalent of 4 days of the 
course including days one and two which are mandatory; 
it will be acceptable to include half days in the total.
DAFNEplus (intervention arm)
DAFNEplus will be delivered by trained DAFNE educators 
in the NHS. In DAFNEplus, those delivering the interven-
tion are referred to as ‘facilitators’, as opposed to ‘educa-
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diabetes specialist nurses, dietitians and physicians, all 
of whom will be using DAFNE principles as an integral 
part of the management of T1D in adults. DAFNEplus is 
a complex intervention, defined by the Medical Research 
Council18 as having ‘several interacting components’, 
described in summary below.
The development of the content and structure of the 
DAFNEplus programme was informed by the Behaviour 
Change Wheel framework.19 The intervention’s proposed 
functions are served by behaviour change techniques 
(BCTs), specified in the hierarchical BCT Taxonomy 
V.1,20 deemed its ‘active ingredients’.21 The develop-
ment of the DAFNEplus programme (described in 22) 
was informed by expert consensus, integrating data on 
participant- generated and clinician- generated barriers 
and facilitators to sustaining DAFNE with the findings 
from a synthesis of qualitative evidence about post- 
DAFNE challenges.22 Prior to this RCT, the DAFNEplus 
programme was piloted in three NHS Diabetes Centres.
The DAFNEplus programme comprises three 
components:
DAFNEplus course
The group- based course component of the DAFNE-
plus programme is delivered one day per week, over five 
consecutive weeks, and is based on a revision of the stan-
dard DAFNE 5- week curriculum, with a view to strength-
ening and sustaining self- management behaviours over 
a longer term to enable them to achieve blood glucose 
levels closer to target. Participants will attend an indi-
vidual precourse appointment approximately two weeks 
before the course which serves as their introduction to 
the programme, during which they are given access to 
and trained in using the DAFNEplus technology (see 
below), as well as a bolus calculator.
New sessions included in the DAFNEplus course include 
technology assisted individual review, emotional aspects 
of living with diabetes and its management, harnessing 
social support and behavioural change—including addi-
tional support for action planning and relapse preven-
tion to help participants achieve their self- management 
goals. The curriculum was revised to be consistent with 
modern approaches to the recommended language used 
in diabetes care.23 Requirements to qualify as adherent 
for statistical purposes are defined above.
Structured follow-up support
The model of structured follow- up support builds on 
the clinical and behavioural skills introduced during the 
course to enable participants to maximise the efficacy of 
key DAFNEplus principles to improve self- management 
and achieve/sustain glycaemic targets. As part of the trial, 
up to five one- to- one consultations (face- to- face, tele-
phone or in some centres, web- based video calling) with 
a DAFNE facilitator will be offered, delivered at progres-
sively wider spaced intervals during the 12 months after 
the course. Appointments are supported by paperwork to 
‘activate’ both the participant and the facilitator prior to 
meeting.
The purpose of these individual sessions is to review 
participants’ progress with managing their diabetes, 
including progress with their action plans, review blood 
glucose data on the DAFNEplus website, revise course 
material, address any additional clinical needs and sign-
post participants to any relevant sources of support. In 
addition, ad hoc support by telephone, email or web- 
based video calling will be available, as necessary. To 
qualify as adherent for statistical purposes, participants 
will need to have attended a minimum of three follow- up 
sessions.
Digital technology
The DAFNEplus programme incorporates two forms of 
digital technology via the DAFNEplus website and box. 
Participants will be given access and training at the pre- 
course appointment, so that they can use the technology 
before and throughout the 12- month programme. The 
DAFNEplus box (Withcare+) transmits, stores and displays 
blood glucose (and other) data on a secure- server via the 
DAFNEplus website in formats to help people with T1D 
and their HCPs recognise and interpret blood glucose 
patterns. The website also includes an e- learning section 
to help maintain knowledge of the DAFNEplus approach.
Training and supervision
A clinical psychologist who specialises in diabetes and 
is experienced in training diabetes professionals in 
behavioural change skills will lead the development and 
delivery of DAFNEplus facilitator training and supervision. 
The training programme is delivered over a maximum of 
five days and will build on the existing skill- set of DAFNE 
facilitators but also draw on additional behavioural 
science to deliver the revised curriculum.
Throughout the trial, facilitators in each centre will 
be offered supervision by the clinical psychologist and a 
DAFNEplus facilitator. Supervision will comprise weekly 
teleconferences before and during the first DAFNE-
plus course, weekly email supervision (for subsequent 
courses) and ad hoc remote support to allow issues that 
arise to be addressed in a timely manner during the 
trial.
Criteria for withdrawal from or discontinuation of trial 
treatment
The decision regarding participation in the study is 
entirely voluntary, and consent regarding study partici-
pation may be withdrawn at any time without affecting 
the quality or quantity of future medical care. No study- 
specific interventions will be undertaken before informed 
consent has been obtained.
A participant will be classed as complete if they have 
continued in the study until the last protocol defined inter-
vention (final 12- month outcome assessment), although 
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Random allocation
On recruitment of centres and following ethical 
approval, the participating centres will be randomised 
on a 1:1 basis to control or the intervention arm of the 
trial by the trial statistician. As there are numerous strat-
ification variables that have been identified as clinically 
important and the small number of randomising centres, 
a covariate constrained methodology24 will be employed. 
The centres will be matched on the number of patients 
within the centre, number of educators within the centre 
and number of previous DAFNE courses delivered (as a 
marker of centre experience) to balance centres between 
the two arms of the trial.
Blinding
Due to the nature of the intervention, it is not possible 
for members of the study team working directly with 
participants or the intervention to be blinded. Addi-
tionally, the blinding of the statistician is problematic 
due to the cluster level randomisation. Statisticians are 
usually involved within Trial Management Group (TMG) 
discussions and have access to status reports where the 
potential for unintentional unblinding is a high possi-
bility. It is considered important for the statistician to be 
included in these aspects of the trial management and 
so after discussion with senior statisticians at the Clinical 
Trials Research Unit (CTRU) and the independent statis-
tician on the Trial Steering Committee (TSC), it has been 
deemed acceptable that the statisticians are not blind 
within this study.
Outcomes
Table 1 shows a breakdown of all outcome measures.
Biomedical outcomes
The primary biomedical outcome is an integrated 
measure of glucose levels over the previous 4–6 weeks, 
defined by HbA1c (using a centralised assay to ensure 
standardisation). The primary endpoint is HbA1c at 12 
months, in those entering the trial with HbA1c >7.5% (58 
mmol/mol), and HbA1c at 6 months is the secondary 
endpoint.
Our primary aim is to compare HbA1c between the 
two arms and we have therefore confined our primary 
analysis to those with raised A1c values at baseline. We, 
therefore, excluded those with an HbA1c below 7.5% (58 
mmol/mol) when calculating the primary endpoint as 
these people have less need to reduce their HbA1c.
However, we have included participants with lower A1c 
values to ensure we can calculate important secondary 
outcomes part rates of hypoglycaemia, and other biomed-
ical and psychological outcomes. We have estimated the 
expected proportion of participants with A1c values above 
7.5% at 75% of those currently undertaking DAFNE 
courses based on a national research database.
Other secondary outcomes are the number of partic-
ipants achieving either an HbA1c <7.5% (58 mmol/
mol) or a decrease in HbA1c of ≥0.5% (≥5.5 mmol/mol) 
which will be calculated at both 6 and 12 months post 
course. These cut- off points are recognised throughout 
the diabetes research community as being clinically rele-
vant.25 We will also collect and analyse 24- month outcome 
data (HbA1c and severe hypoglycaemic episodes) and 
analyse after the main study has closed and been reported 
based on locally available clinical data which is routinely 
collected annually in clinical centres.
Other secondary biomedical outcomes will include: 
Severe hypoglycaemia, as defined by the American 
Diabetes Association,26 denotes severe cognitive impair-
ment requiring external assistance for recovery, both 
rates and proportion of those affected; Diabetic ketoaci-
dosis, both rates and proportion of those affected; weight; 
body mass index; blood pressure; lipids; albumin/creati-
nine ratio.
Psychological outcomes and process evaluation
Quantitative outcomes
Psychological outcomes and process measures will be 
collected via self- completed postal or online question-
naires at baseline, course completion, 3, 6, 9 and 12 
months (see table 1).
The primary psychological outcome is the impact of 
diabetes on quality of life assessed at 12 months using 
a 15- domain version of the Audit- Dependent Diabetes 
Quality of Life Questionnaire.27
Additional psychological constructs are assessed with 
validated questionnaires and study- specific individual 
items, based on: existing knowledge about their associa-
tion with the trial’s primary biomedical outcome (HbA1c) 
and primary psychological outcome (diabetes- specific 
quality of life), including the findings of the YourSAY 
survey28; previous work with the DAFNE intervention, and 
the theoretical framework underpinning the DAFNEplus 
intervention development and possible treatment mech-
anisms.19 29 30
Qualitative outcomes
Interviews will be undertaken with a subset of partici-
pants randomised to the intervention at baseline, course 
completion, 3 months and 12 months (figure 1) to 
explore how key elements of the intervention influence 
and inform changes to, and maintenance of, key self- 
management behaviours over time. Facilitators will be 
interviewed from across the intervention sites to explore 
their experiences of intervention delivery and their views 
about the training, resourcing and support staff would 
need to deliver DAFNEplus in routine care.
Fidelity assessment
We will explore fidelity of delivery using two methods to 
assess the extent to which the intervention content spec-
ified in the DAFNE/DAFNEplus manuals is delivered as 
intended: self- report checklists completed by educators/
facilitators, and objectively analysed delivery from session 
audio recordings. Fidelity of delivery will be assessed 
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3 months* 6 months* 9 months* 12 months*
Demographic/clinical
Glycaemic control (HbA1c) N/A ✓     ✓   ✓
Lipids N/A ✓         ✓
Body mass index (height/weight) N/A ✓     ✓   ✓
Blood pressure N/A ✓     ✓   ✓
Episodes of severe hypoglycaemia N/A ✓     ✓   ✓
Episodes of ketoacidosis N/A ✓     ✓   ✓
Demographics Individual items ✓     ✓   ✓
Hypoglycaemia awareness Gold score36 and DAFNE 
hypo awareness measure
✓     ✓   ✓
Primary psychological outcomes
Diabetes- specific quality of life ADDQoL-1527 ✓     ✓   ✓
Secondary psychological outcomes
Diabetes distress Problem Areas In Diabetes 
(short- form)37
✓     ✓   ✓
Diabetes- specific quality of life Dawn Impact of Diabetes 
Profile38
✓     ✓   ✓
Diabetes- specific positive well- being 4- item sub- scale of the Well 
Being Questionnaire39
✓     ✓   ✓
Fear of hypoglycaemia Hypoglycaemia Fear 
Survey-11 (short- form)40
✓     ✓   ✓
Health status Health and Self- Management 
in Diabetes41
✓     ✓   ✓
Health status EQ- 5D- 5L42 ✓     ✓   ✓
Healthcare utilisation Individual items ✓     ✓   ✓
Resource allocation Individual items   ✓         
Process measures




✓ ✓ ✓   ✓   




✓ ✓ ✓   ✓   
Diabetes strengths and resilience Diabetes Strengths and 
Resilience Questionnaire45
✓ ✓ ✓   ✓   
Beliefs about capabilities: diabetes 
self- care
Confidence in Diabetes 
Scale*46
✓ ✓ ✓   ✓   




✓ ✓ ✓   ✓   
Diabetes- specific self- care 
behaviours
Diabetes Self- Care 
Behaviours48
✓ ✓ ✓   ✓   
Beliefs about consequences of 
engaging in DAFNE behaviours and 
weaving diabetes management into 
everyday routines
Individual items* ✓ ✓ ✓   ✓   
Evaluation of technology (DAFNEplus 
website in intervention group and 
bolus calculator in control group)
System usability scale49   ✓ ✓   ✓   
*Description about the development and modifications of these questionnaires and individual items are detailed in online supplemental material 4.
ADDQoL, Audit of Diabetes- Dependent Quality of Life Questionnaire; DAFNE, Dose Adjustment For Normal Eating; EQ- 5D- 5L, EuroQol-5 Dimension 
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assess any loss of treatment differentiation and potential 
contamination between the two arms.
1. Self- report checklists: Facilitators will complete check-
lists after each session. Each checklist lists the com-
ponents intended to be delivered in each session 
(according to the manual). These components corre-
spond to different BCTs. Each component will be rated 
as fully, partially or not delivered, with space for addi-
tional comments. The proportion of intended compo-
nents rated as partially/fully delivered by educators/
facilitators will be calculated, with <50% of intended 
content delivered classified as low fidelity; 51%–79% 
as moderate fidelity, and 80%–100%’ as high fidelity.31
2. Objectively analysed delivery: A subsample of group 
course sessions in both arms will be audio- recorded 
and transcribed verbatim. Transcripts will be coded 
into component BCTs using an established taxono-
my.20 BCTs identified in each session transcript will be 
compared with corresponding section of the interven-
tion manual that specifies which BCTs are intended to 
be delivered in that session. Fidelity will be calculated 
in terms of the percentage of manual- specified BCTs 
delivered as intended. Additional BCTs delivered that 
are not specified in the curricula will also be noted.
Detailed plans for the process evaluation are in online 
supplemental material 2.
Health economic outcomes
Table 1 details the health economic data collected in the 
trial. In addition, data collected from the DAFNEplus 
website will be used to cost the intervention. The analysis 
population for the health economic analyses will include 
all trial participants, as it is important that the analysis 
of health economic data includes all participants who 
would be eligible to receive DAFNEplus (if it were to be 
implemented). In line with the statistical analysis, we will 
conduct subgroup analyses in participants with an HbA1c 
≤7.5% and >7.5% (58 mmol/mol).
Two health economic analyses will be conducted, a 
primary long- term analysis using the Sheffield T1D Policy 
Model and a secondary analysis of the data collected in 
the trial. All health economic analysis will compare the 
incremental cost- effectiveness ratio of DAFNEplus versus 
DAFNE to standard National Institute for Health and Care 
Excellence thresholds to determine cost- effectiveness.32 




Study centres are only required to report as adverse events 
episodes of diabetic ketoacidosis and severe hypogly-
caemia which while not requiring admission to hospital 
have been noted by either the participant or their rela-
tive/partner etc. These will be recorded on the data 
collection form and database.
Reporting
We do not anticipate many Serious Adverse Events related 
specifically to DAFNEplus or standard DAFNE but will 
report any which are deemed related to the study inter-
vention and or are unexpected to the Sponsor and the 
REC in line with best practice.
Sample size
It is expected that there will be 882 patients referred 
for DAFNE courses within the 15- month recruitment 
window and of these it is expected 75% (662 patients) 
will be recruited, equivalent to 47 participants at each of 
the 14 centres. From current DAFNE data, a further 25% 
are expected not to meet the primary analysis population 
criteria of baseline HbA1c greater than 7.5% (58 mmol/
mol), leaving 497 participants. Finally, we anticipate 15% 
of participants to be lost to follow- up by the 12- month 
stage, therefore giving a primary analysis population of 
422 participants. The sample size takes into account the 
design effect associated with the cluster design of the 
study. With an intracluster correlation coefficient (ICC) 
of 1.5% (from previous DAFNE data) and 30 participants 
per cluster (422 participants over 14 centres) the design 
effect is 1.435 leaving the effective total sample size of 
n=294 participants (n=147 per arm).
Using a two sample comparison of mean HbA1c at the 
12- month follow- up with two- sided alpha of 5%, a correla-
tion of 0.5 between baseline and final values and a SD of 
1.45 (from previous DAFNE data), the trial sample gives 
92% power to detect a 0.5% difference in HbA1c (the 
minimum clinically important difference) between the 
two treatment groups in the study.
Statistical analysis
The primary analysis population will be participants that 
had an HbA1c greater than 7.5% (58 mmol/mol) at base-
line and the analysis will be completed on an intention- 
to- treat (ITT) basis. This primary analysis is to assess the 
difference between the two treatment groups on the 
mean HbA1c at 12 months which will be completed using 
a multiple linear regression model with coefficients esti-
mated using generalised estimating equations to account 
for the clustering design. A 95% confidence interval for 
the difference between the two treatment groups will be 
presented. Appropriate covariates will be included in the 
model, along with the participant’s baseline HbA1c, to 
adjust the treatment effect accordingly.
The secondary analysis population is all consenting 
participants in the trial and analysis will again be 
completed on an ITT basis. This population will also be 
used to assess the difference in psychological outcomes 
between the two treatment groups using the same model 
as for the primary analysis.
A full statistical analysis plan has been written and was 
circulated to the TMG and TSC before being signed- off. 
This is available in online supplemental material 5. All 
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Consolidated Standards of Reporting Trials 2010 state-
ment for cluster RCTs.33
Data collection and management
Case report forms will be completed by DAFNE facil-
itators/educators at each study visit. Follow- up ques-
tionnaires will be self- completed by participants at each 
follow- up point. Participants will be allocated a unique 
identification number to identify them throughout the 
trial.
Plans to promote retention and follow- up of all trial 
participants include research appointments being sched-
uled and followed up by their clinical teams at 6 months 
and 12 months. Overdue questionnaires are followed- up 
with an email reminder and then telephone call from 
CTRU. All participants received email newsletters to 
update them on trial progress.
Data will be entered onto the DAFNEplus database 
on CTRU’s secure online system, hosted on University 
of Sheffield servers. Access is restricted such that users 
can enter and view only information required to perform 
their role.
Identifiable data will be shared with CTRU and the 
supporting study team and DAFNEplus website teams. 
Consent will be obtained from the participant for this 
to occur. Data will be stored securely on access- restricted 
network drive folders in accordance with CTRU standard 
operating procedures (SOPs).
All consent forms and questionnaires will be kept 
in a locked filing cabinet in a secured area and will be 
retained for a minimum of 5 years after study completion, 
in accordance with the sponsor’s archiving requirements. 
Sheffield CTRU may request consent forms to be sent 
from the research site to the CTRU via post or email as 
part of remote monitoring procedures.
The nature, frequency and intensity of trial monitoring 
will be outlined in the site monitoring plan, which will be 
devised in accordance with CTRU SOPs.
Patient and public involvement
In addition to the patient representation on the 
trial oversight committees, this trial is supported by a 
patient advisory group who have and will continue to 
meet regularly during the conduct of the trial (and the 
wider programme grant). Patient input has been sought 
throughout on the trial and intervention design, the 
informational material to support trial conduct and 
patient burden.
Trial oversight committees
Two oversight committees have been established to 
oversee the conduct of this trial— the TSC and TMG, 
the composition of each is listed at the end of this paper. 
A Data Monitoring and Ethics Committee has not been 
convened, on the grounds that the study is low risk, in 
line with CTRU SOP GOV003. This has been approved by 
the Sponsor and TSC.
ETHICS AND DISSEMINATION
The RCT was not initiated until the protocol, informed 
consent forms and participant information sheets 
received approval from the Research Ethics Committee, 
the Health Research Authority and local Capacity and 
Capability is confirmed by the respective NHS Research 
and Development departments. MHRA (Medicines and 
Healthcare products Regulatory Agency) approval was 
not required for this study.
The RCT is being conducted in accordance with the 
ethical principles that have their origin in the Declaration 
of Helsinki34; the principles of GCP, and the UK Frame-
work for Health and Social Care Research.35
Outputs from the trial will be generated in accordance 
with the communication and dissemination strategy. 
A number of academic outputs will be produced as the 
data are analysed from the trial. Journals will be selected 
based on the highest possible impact. Other stakeholder- 
specific outputs in relevant formats will also be produced 
for commissioners, third sector and user advocacy 
organisations.
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Public title DAFNEplus Cluster RCT 
 
Scientific title A cluster randomised controlled trial (RCT) of the DAFNEplus (Dose 
Adjustment for Normal Eating) intervention: A lifelong approach to 










Type 1 diabetes 
Intervention(s) DAFNEplus (Dose Adjustment for Normal Eating) intervention 
 
Key inclusion and 
exclusion criteria 
Inclusion criteria:  
• Adults (≥18 years);  
• Diagnosis of type 1 diabetes for at least 6 months, or post-
honeymoon; 
• Prepared to undertake multiple daily injection (MDI) therapy;  
• Prepared to undertake frequent self-monitoring of blood 
glucose; 
• Confirms availability to attend all sessions as part of the 
intervention; 
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• Investigator has confidence that the patient is capable of 
adhering to all the trial protocol requirements. 
 
Exclusion criteria:  
• Current use of continuous subcutaneous insulin infusion (CSII) 
pump therapy 
• HbA1c > 12%/108 mmol/mol (Investigators can use their 
judgement, informed by standard DAFNE guidelines and in 
agreement with the trial team, to include participants with HbA1c 
>12%/108 mmol/mol). 
• Serious diabetic complications (e.g. blindness, renal dialysis). 
(Investigators can use their clinical judgement, informed by 
standard DAFNE guidelines and in agreement with the trial 
team). 
• Other serious co-morbidities e.g. psychosis, diagnosed eating 
disorder (Investigators can use their clinical judgement, 
informed by standard DAFNE guidelines and in agreement with 
the trial team). 
• Previous participation in standard DAFNE course less than 5 
years before proposed study enrolment date 
• Unable to speak/hear/understand/read write in English 
• Unable to give written informed consent 
 
Study type Multi-centre cluster randomised controlled trial with process 
evaluation and economic evaluation, comparing DAFNEplus to 
standard DAFNE for adults with type 1 diabetes. 
 






662 participants – 47 per centre. 
 
Fourteen secondary care diabetes centres in the National Health 
Service in England and Scotland 
 
In addition, we aim to recruit 20 DAFNEplus facilitators to take part 
in qualitative interviews for the process evaluation. 
 




The primary biomedical outcome is glycaemic control, defined as 
the change in HbA1c at 12 months (using a 
centralised assay to ensure standardisation), in those entering the 
trial with HbA1c >7.5% (estimated at 75% of those currently 




Secondary biomedical outcome: 
Number of participants achieving either an HbA1c <7.5% (58 
mmol/mol) or a decrease in HbA1c 
of ≥0.5% (≥5.5 mmol/mol) (using a centralised assay to ensure 
standardisation). These endpoints 
will be calculated using data collected at baseline and 12 months 
after the course. 
 
Other secondary biomedical outcomes will include: 
1. Severe hypoglycaemia, as defined by the American Diabetes 
Association, denotes severe 
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cognitive impairment requiring external assistance for recovery, 
both rates and proportion of 
those affected, measured at baseline at 12 months after the course 
2. Diabetic ketoacidosis, both rates and proportion of those affected, 
collected at baseline and 
12 months after the course 
3. Weight, measured at baseline and 12 months after the course 
4. Body Mass Index, measured at baseline and 12 months after the 
course 
5. Blood pressure, measured at baseline and 12 months after the 
course 
6. Lipids, measured at baseline and 12 months after the course 
7. Albumin/ creatinine, measured at baseline and 12 months after 
the course 
 
The primary psychological outcome is the measurement at 12 
months of the Audit-Dependent Diabetes Quality of Life 
Questionnaire (ADDQoL-15), a thirty-item measure of diabetes-
specific quality of life. 
 
Psychological outcomes, measured at baseline, course completion, 
3, 6 and 12 months: 
1. Dawn Impact of Diabetes Profile  
2. Problem Areas in Diabetes Scale   
3. Diabetes-specific positive well-being  
4. Hypoglycaemia Fear Survey  
 
Process measures:  
5. Diabetes Management Experiences Questionnaire  
6. Self-Regulation/Behavioural Regulation Questionnaire  
7. Diabetes Strengths & Resilience Questionnaire  
8. Confidence in Diabetes Scale assesses beliefs about capabilities 
(self-efficacy).  
9. Diabetes Self-Care Behaviours  
10. Hypoglycaemia Confidence Scale   
11. Beliefs about consequences of engaging in DAFNE behaviours 
and weaving diabetes management into everyday routines.  
12. The System Usability Score  
13. Use and dose received of the DANFEplus programme assessed 
via logs of attendance at group and individual sessions, and use of 
the DANFEplus website 
 
Hypoglycaemia Awareness 
14. Hypoglycaemia awareness assessed via Gold score 
 
Health economic measures assessed at baseline, course 
completion, 6 and 12 months using: 
1. Health status – EQ-5D-5L 
2. Health and Self-Management in Diabetes HASMID 
3. Healthcare utilisation using a bespoke questionnaire 
4. Contact between professionals and course participants will also 
be recorded at each site using questionnaires and data from the 
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Supplementary material 2 – Protocol for DAFNEplus Process evaluation 
 
Aims and research questions 
Understanding processes is as important as evaluating outcomes; process 
evaluations are complementary to outcomes evaluations and provide knowledge and 
information of equal value. Process evaluations aim to understand the functioning of 
an intervention by examining its implementation, mechanisms of impact and how 
contextual factors (i.e. factors external to the intervention/individual receiving the 
intervention) might affect its delivery and receipt [1,2]. Without this knowledge we may 
be able to establish from an outcome evaluation that an intervention ‘works’, but we 
will be presuming that the intended intervention was delivered and is effective, and we 
will not necessarily know how, or why, the intervention works and, hence, if it would 
have the same clinical and psychological effect if rolled out from a trial situation into 
routine clinical practice. With a complex intervention such as DAFNEplus it may well 
also be that some elements are more vital to its success than others; hence it is very 
important that we understand and explore the mechanisms of change on outcome 
from the perspectives of those receiving the intervention, as well as unintended 
consequences arising from the delivery and receipt of the intervention. 
 
Our overarching research questions are: 
 
1. Does the DAFNEplus intervention ‘work’ in the ways intended? If not, 
why not?  
 
2. What are the implications of the findings of the process evaluation for 
the rollout of DAFNEplus in routine clinical practice? 
 
To answer these over-arching questions, a series of over-lapping sub-questions will 
be explored: 
 
a) What mechanisms change impact on glycaemic control? That is, how do the 
different elements of DAFNEplus (knowledge/skills, technological, structured 
follow-up), individuals’ interaction with these elements, and individual 
psychological differences trigger changes in and maintenance of key diabetes 
self-management behaviours? The theoretical model underpinning the 
DAFNEplus programme assumes that diabetes self-management behaviours 
are among the principal determinants of glycaemic control. 
 
b) What mechanisms of change impact on diabetes-specific quality of life?  
 
c) What are participants’ experiences of, and views about, key elements of the 
DAFNEplus intervention1 and how do these influence and inform changes in, 
and maintenance of, key diabetes self-management behaviours over time?  
 
                                                             
1
 As a result of work undertaken in the pilot phase and MRC guidance to focus on key areas of 
uncertainty of greatest interest to academic and clinical audiences, a decision has been made to focus 
upon the technological and resilience/self-compassion elements of the programme. 
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d) To what extent is the intervention delivered as intended and are there variations 
between sites and individuals as to how the DAFNEplus intervention is 
delivered? What are the reasons for any variations? 
 
e) What impact (practical and emotional) does intervention delivery have on 
facilitators and their workloads; what resourcing and support would facilitators 
and their colleagues need to deliver DAFNEplus in routine clinical practice? 
 
f) Do any unintended consequences arise from the delivery and receipt of the 
DAFNEplus intervention, for participants and/or facilitators? 
 
The data sources for each of the sub-questions are shown in table 1. 
 
Table 1 – Data sources for the process evaluation 
Research Question Data source(s) 
a) What mechanisms of change impact 
on glycaemic control? 
 
• Questionnaire study 
• Process outcomes  
• Fidelity assessment 
• Qualitative (from DAFNEplus pilot 
study) 
 
b) What mechanisms of change impact 
on diabetes-specific quality of life 
• Questionnaire study 
• Process outcomes 
 




d) To what extent is the intervention 
delivered as intended? 
• Fidelity assessment 
• Qualitative 
 
e) What impact does intervention 




f) Do any unintended consequences 
arise from the delivery and receipt of 
the DAFNEplus intervention? 
• Qualitative 
• Questionnaire study 
• Process outcomes 
• Fidelity assessment 
 
 
The process evaluation is composed of three interlinking components: (1) qualitative, 
(2) quantitative and (3) assessment of fidelity of delivery. 
 
(1) Qualitative component 
 
1.1 Overview 
The qualitative component of the process evaluation will be informed by realist and 
Normalization Process theory (NPT) [3,4]. These choices arise from our recognition 
that context (i.e. factors external to the DAFNEplus intervention and/or the individual 
receiving the intervention) may influence how the intervention is delivered in different 
centres and how it is received by different individuals. It is also recognised that, when 
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a complex intervention, such as DAFNEplus, is implemented it can have unintended 
consequences, which may need to be investigated and, hence, that a flexible and 
adaptive study design will be required. 
 
An iterative, inductive approach will be used wherein data analysis will commence as 
soon as data collection begins [5]. This will allow issues arising during early phases of 
qualitative data collection to inform questions asked in later phases and possibly also 
sampling. The qualitative research will also be responsive to other aspects of the 
process evaluation, including the fidelity work. Hence, while case studies will comprise 
the main element of the qualitative research (see below), costings have been included 
to allow, if necessary, one-off interviews to be undertaken with a ‘booster’ sample of 
patients, facilitators and/or other individuals in the event that the quantitative/fidelity 
components of the process evaluation highlight issues which require qualitative 
explanation. One example might be that, if the fidelity work highlights significant 
variations between trial sites as to how the DAFNEplus intervention is delivered, we 
may decide to interview additional facilitators to better understand why this might be 
the case. 
 
1.2 Qualitative study design: case study approach 
A case study approach will be used because it permits detailed exploration of if, how 
and why the intervention works in different contexts [6]. Each case will comprise: (a) 
participants who will be interviewed before, during and following completion of 
DAFNEplus, (b) their facilitators who will be interviewed after the participant’s closeout 
from the trial, (c) information about the input and care the participant receives as part 
of DAFNEplus and their engagement with DAFNEplus technologies/resources. It will 
be possible to access this information via clinical records, the Glucollector website and 
information documented in case report forms and stored on PROSPECT (the CTRU 
database). Where identifiable clinical information needs transferring between NHS 
and University sites files will be encrypted and nhs.net accounts or Google Drive will 
be used. As part of the process evaluation, we will also have access to recordings of 
participants’ face-to-face follow-up sessions with facilitators – these data are being 
collected for the fidelity assessment work, and data on utilisation of DAFNEplus 
technological components and adherence. Researchers from the University of 
Edinburgh will also sit in some DAFNEplus sessions as observers, to familiarise 
themselves with the processes and material to inform the case studies. 
 
Participant Sampling 
Two or three participants from each of the seven DAFNEplus sites will be selected for 
the qualitative work, and these individuals will be purposively sampled so there is 
representation of people of different ages, HbA1c levels, diabetes duration, gender, 
occupation, educational background, personal circumstance (e.g. single, partnered, 
parent) and place of residence (e.g. urban and rural locations).  
 
Data collection: participant interviews 
Selected participants will be interviewed at four time-points: prior to attending their 
course, following their course, and 3 and 12 months post course. Interviews will be 
informed by topic guides. Prior to undertaking a follow-up interview, a participant’s 
previous interviews will be reviewed. As well as including more generic questions, 
follow-up interviews will be tailored to allow for follow-up of specific issues raised by 
particular individuals.  Questions explored in the post course, 3 and 12 month 
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interviews will also take account of a review of information collected in medical 
records, via DAFNEplus technology and audio recorded follow-up sessions. Interviews 
will take place by telephone (unless an individual requests a face-to-face interview) at 
a time most convenient to the participant. All interviews will be digitally recorded with 
consent. It is anticipated that each interview will take 60 minutes to complete.  
 
Facilitator interviews 
Each participant’s facilitators (n=1-2 per participant) will be interviewed following their 
close-out from the trial. If the participant received care from more than two facilitators 
as part of DAFNEplus we will ask them to nominate the two individuals from whom 
they felt they had the most input. 
 
Facilitators will be interviewed once following the participant’s close-out from the trial. 
This decision has been made partly for pragmatic reasons (i.e. we do not want to make 
excessive demands on the health professionals’ time) and also because it will be 
possible to access information about the participant’s care and the decisions made 
from the contact logs, clinical records and recordings of follow-up sessions. It is also 
recognised that, if facilitators are made aware that the participant is included in the 
process evaluation, this might influence or bias the care which is given, although 
participants will not be prohibited from telling their facilitators they are taking part in 
the qualitative research should they choose to do so. 
 
Facilitator interviews will explore two key areas: (1) their views about, and experiences 
of, providing care and support to the case study participant; and (2) the facilitator’s 
more general experiences of recruiting into the trial and delivering the DAFNEplus 
intervention. 
 
Data collection: facilitator interviews  
The facilitators’ interviews will be informed by topic guides, although each individual’s 
interview will also be tailored to explore issues specific to the participant who forms 
the focus of the case study (being careful to ensure that patient confidentiality is not 
breached). Interviews will take place by telephone at a time most convenient to the 
facilitator and will be digitally recorded. 
 
1.3 Data analysis 
Each participant’s four interviews will be read through repeatedly and cross-compared 
with particular attention being paid to continuities and changes in their diabetes self-
management practices over time, and the reasons for these. To aid comparison and 
identify where behaviour change has happened and why, ‘critical incidents’ will be 
extracted and compared (a ‘critical incident’ comprises data where a 
behaviour/decision/experience is described in detail, including the contextual and 
antecedent factors leading up to it and the consequences arising from it [7,8]). To help 
identify reasons for behaviour change, maintenance and lapses, data from the 
facilitator interviews, and recordings of follow-up sessions and case reports will also 
be used to help interpret and provide context to analysis of participant interviews.  
 
Facilitator interviews will be cross-compared to identify issues and experiences which 
cut across different accounts [5]. Depending on the findings of the fidelity work, 
facilitator interviews may also be analysed in clusters (e.g. facilitators belonging to 
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‘adherent’ vs ‘non-adherent’ sites), to better understand reasons for individual/site 
differences in how the DAFNEplus intervention was delivered.  
 
Key objectives of the analysis of the participant interviews are to better understand the 
mechanisms of impact in order to: (a) inform analysis of the quantitative data collected 
for the process evaluation; and (b) aid interpretation of quantitative data collected for 
both the process and outcomes evaluations. Key objectives of the analysis of the 
facilitator interviews are to offer insights which might: (a) aid interpretation of the 
participant case study data; (b) help explain findings from the fidelity work; (c) aid 
interpretation of trial outcome data; and, (d) offer insights relevant to decision-making 
about the possible rollout of DAFNEplus following the trial.  
 
A key area for reflection 
It needs to be recognised that, by interviewing participants at four time-points, and 
because of the kinds of questions which will be asked, the qualitative study could, 
potentially, have an impact on how this small group of participants understand, engage 
with, and experience the DAFNEplus intervention. Care will be made to emphasise to 
participants that the qualitative study is separate to DAFNEplus and it is our intention 
to understand their experiences rather than to influence their behaviours. Whilst we 
may not be able to diminish the impact that this has on these participants, we hope 
that the overall impact will be minimal due to the small sample size potentially affected.  
 
(2) Quantitative component 
 
2.1 Overview 
A longitudinal, questionnaire study design has been adopted to determine the impact 
of the RCT on: a) our primary psychological outcome (diabetes-specific quality of life), 
b) secondary psychological outcomes and c) for the quantitative aspect of the process 
evaluation. That is, to identify the mechanisms of change that predict glycaemic control 
and diabetes-specific quality of life.  
 
All participants in the intervention (DAFNEplus) and control (DAFNE) arms of the RCT 
will be given questionnaires to complete at baseline (up to 4 weeks prior to 
commencing the course) and at course completion, 3, 6, 9, 12 months post-course 
(see section 7 and Table 1).  At baseline, the point at which participants will be more 
motivated to participate (pre-trial), they will be asked to complete all outcome and 
process questionnaire measures. To reduce participant burden, at course completion, 
3- and 9-months they will only be asked to complete process measures. At 6 and 12-
months they will be asked to complete the primary and secondary outcome measures 
only. Participants will be given the option of completing the questionnaire packs online 
or as a hard copy. Our choice of questionnaires (see section 7), assessing different 
constructs, have been selected according to existing knowledge about their 
association with the trial’s primary outcome (HbA1c) and diabetes-specific quality of 
life (primary psychological outcome), the results of the YOURSAY survey 
(unpublished), our former work with the DAFNE intervention, and based on the 
theoretical framework that underpins the new intervention development work and 
possible treatment mechanisms [9–11]. Brevity of the questionnaires and participant 
burden have also been a key consideration in our rationale for selection.  
 
2.2 Analysis 
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The use of a repeated measures, longitudinal design will permit analysis of our primary 
and secondary psychological outcomes, as well as both the short- and long-term 
predictors and mediators of outcome (HbA1c and ADDQoL-15) using Structural 
Equation Modelling. SEM combines confirmatory and exploratory purposes. We will 
test our proposed model of the long-term predictors and mediators of outcome and 
then, if necessary, re-test this based on changes suggested by SEM modification 
indices [12]. The model will partially be informed by the qualitative work (described in 
section 1 above).  
 
(3) Assessment of fidelity of delivery 
 
3.1 Introduction 
Behaviour change interventions are susceptible to variation in implementation, and 
are not always delivered as planned [13].  Intervention fidelity refers to the 
methodological strategies used to assess, monitor and enhance the integrity, that is, 
reliability and validity of behaviour change interventions [13].  The extent to which 
interventions are delivered as planned indicates internal and external validity, and 
needs to be known if the trial results are to be accurately interpreted and replicated.  
If fidelity is low, it is uncertain whether a change in outcome variables is due to the 
intended intervention, or to unknown factors that may have been added or omitted; 
alternatively, if no positive change is observed, it cannot be determined whether this 
is due to an inefficient intervention or a lack of intervention fidelity. This means that 
ineffective treatments risk being implemented and disseminated, and potentially 
effective treatments prematurely discarded [13]. 
 
The development of the content and structure of the DAFNEplus programme was 
informed by the Behaviour Change Wheel (BCW) framework [11]. The intervention’s 
proposed functions are served by behaviour change techniques (BCTs), specified in 
the hierarchical Behaviour Change Technique Taxonomy v1 (BCTTv1; [14]), which 
are its ‘active ingredients’ [15]. The DAFNEplus intervention contains manual-
specified BCTs as its active ingredients proposed to effect behaviour change (e.g. 
action planning, goal setting, and information on health consequences of the 
behaviour), together with principles for delivery specific to the DAFNEplus intervention 
that were identified during an expert consensus process (e.g. focus on the positives, 
emphasise individual autonomy).  The fidelity analysis will involve assessment of the 
delivery of BCTs. 
 
Fidelity of delivery of BCTs will also be assessed in the control arm of the trial 
(standard DAFNE) in order to identify any loss of treatment differentiation between the 
intervention and control arms as originally designed.  Potentially loss of differentiation 
may result from low fidelity of delivery of additional content in the DAFNEplus 
programme, or additional content being delivered in the standard DAFNE programme, 
either unintentionally or as a result of contamination.  
 
3.2 Aims and research questions 
The aim is to explore the integrity of delivery of the DAFNEplus programme trialled in 
the RCT. 
The research questions are: 
• To what extent was the DAFNEplus programme delivered as specified in the 
protocols (course curriculum and follow-up scripts)? Specifically: 
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o What proportion of manual-specified content (i.e. BCTs) was delivered 
by facilitators as intended during the programme sessions? 
o What additional, non-specified BCTs were delivered by facilitators? 
o How did the proportion of manual-specified content delivered differ 
across sessions and sites? 
• What is the extent of treatment differentiation between the content of 





A quantitative fidelity assessment, involving content analysis of intervention materials 
and transcripts of audio-recorded intervention sessions and provider self-rated fidelity 
checklists.  
 
3.3.2 Observed fidelity of delivery assessment 
The direct observation of fidelity via coding of session transcripts will provide an in-
depth assessment of fidelity of delivery in a sub-sample of DAFNEplus and DAFNE 
courses.    
 
Participants 
Facilitators delivering either the DAFNEplus (intervention arm) or standard DAFNE 
(control arm) curriculum in 6 of the 14 participating sites will have their sessions 
recorded.  It is assumed that each of these sites will have at least three facilitators 
delivering the DAFNE or DAFNEplus programmes (i.e. a minimum of 18 participants).  
Informed consent will be obtained from all participants at the selected sites (facilitators 
and patients). As part of the wider RCT., their participation in the programme during 
the course and follow-up sessions will be audio-recorded for training and research 
purposes.   
 
Materials: Coding framework to assess observed fidelity of delivery 
A coding framework will be developed to specify the BCTs to be delivered during the 
five face-to-face DAFNEplus days and the follow-up sessions, and the standard 
DAFNE course sessions, as specified in the facilitator manual.  For each BCT the 
coding framework will include a definition, examples and criteria for potential 
operationalisation in the context of the programme.   
 
Sampling and procedure 
Six sites (2 control and 4 intervention) will be purposively sampled for audio recording 
of all sessions. Selection will be informed by variables such as facilitator experience, 
previous research activity and site activity levels.  
 
Course sessions, and where applicable follow up sessions,  delivered face-to-face, will 
be audio-recorded in both the intervention (i.e. DAFNEplus) arm and control arm (i.e. 
standard DAFNE) [6] at selected sites. Written informed consent for audio-recording 
sessions will be sought from all participants and facilitators. Participants will be 
reassured that transcripts of audio-recorded sessions will be fully anonymised to 
remove any personal or identifiable information.  Facilitators will be supplied with a 
digital audio-recorder and instructions for operating it. Facilitators will audio-record 
sessions and upload recordings to the University of Sheffield secure server via Google 
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Drive which will be accessed by the study manager and authorised members of the 
research team. Transcription will be performed by an external transcription service and 
a confidentiality agreement will be put in place with the transcribers to protect 
participant’s data. 
 
Each DAFNEplus programme comprises circa 40 sessions (one 1:1 pre-course 
session, 35 group ‘course’ sessions and four 1:1 follow-up sessions per participant). 
Each standard DAFNE course comprises circa 35 group course sessions per 
participant. Sessions will therefore be purposively sampled for transcription and 
analysis across both arms, selected sites and courses. Courses will be sampled 
according to key variables, e.g. geographical location, and the timeline for the trial with 
earlier courses preferentially sampled due to staff resource. Sessions may be sampled 
for transcription according to theoretical underpinning of the intervention, and 
evidenced relation to the outcome.  
 
Analysis 
Sampled content of sessions in both the intervention and control arms will be first 
specified by applying the developed coding framework to the sample of selected 
course transcripts. Two researchers will independently read through the session 
transcript line-by-line, using the coding framework to identify and categorise BCTs 
present in the facilitator’s speech. Each identified BCT and delivery principle will be 
rated as fully, partially or not delivered according to the coding framework definition 
and criteria.  Illustrative examples will be extracted into the framework. 
 
To assess and establish inter-coder reliability, the researchers will meet frequently in 
coding workshops at the outset of coding (e.g. initially after coding every transcript 
[16]). Approximately twenty percent of transcripts will be double coded. Inter-rater 
reliability will be assessed by percentage agreement [17].  Reasons for discrepancies 
will be discussed, and the coding framework developed accordingly.  Following 
Hardeman et al. [16], a minimum level of 75% inter-coder agreement [18], described 
as ‘high’ [19,20] will be considered acceptable. After inter-coder reliability has been 
established, researchers will code the remainder of transcripts independently.   
 
Fidelity of delivery will be assessed following the methods of Hardeman et al. [16] and 
Lorencatto et al. [17]. Each of the BCTs specified in the DAFNEplus programme 
(intervention arm) or standard DAFNE programme (control arm) curriculum/scripts will 
be listed in a checklist, together with details such as session number and facilitator 
participant number. The BCTs specified in the coding framework will be rated as: 1) 
fully present, 2) partially present, or 3) absent but should be present. The proportion 
of BCTs delivered as intended will be assessed by dividing the number of fully/partially 
present BCTs by the total number of intended BCTs.  Established criteria will be 
applied to classify extent of observed fidelity of delivery [6]: if < 50% of intended 
content is delivered this will be classified as ‘low’ fidelity; 51-79% as ‘moderate’ fidelity, 
and 80-100%’ as ‘high fidelity’.  
 
Sessions will be grouped into types based on topics where applicable (for example, 
the four sessions covering action planning would be grouped into one type).  An 
‘intended content’ checklist will be produced for each session, and the session 
transcript will only be compared to the checklist for the corresponding session or 
session type, rather than comparison against the full curriculum. Variation in fidelity 
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will be examined according to site and session type. Delivery of any additional content 
will also be examined by assessing the frequency of delivery of any non-specified 
BCTs. This will serve to identify adaptations made whilst delivering DAFNEplus. 
 
Treatment differentiation will be assessed by comparing the content analyses of 
transcripts from the intervention (DAFNEplus) and control (standard DAFNE) 
sessions. BCTs that are fully/partially delivered in transcripts from both arms will be 
compared, and the proportion of BCTs delivered in both arms assessed, with a higher 
proportion of common BCTs delivered representing less treatment differentiation. 
 
3.3.3 Self-reported fidelity of delivery 
 
Participants 
All facilitators delivering either the DAFNEplus (intervention arm) or standard DAFNE 
(control arm) curriculum/scripts in each of the 14 participating sites will provide data 
for the fidelity of assessment delivery.  It is assumed that each site will have at least 
three facilitators delivering the DAFNE or DAFNEplus programmes (i.e. a minimum of 
at least 42 participants).  Informed consent will be obtained from all participants 
(facilitators and patients) as part of the wider RCT. 
 
Materials: Facilitator self-rated checklists 
To obtain a global snapshot of fidelity across all DAFNEplus courses, including those 
that are not transcribed and included in the observed fidelity assessment, self-reported 
facilitator checklists will also be developed and administered to all sites (intervention 
and control).  The checklist will include provision of key information and BCTs that are 
intended to be delivered (i.e. as specified in the pre-course session script, course 
curriculum and follow-up support scripts), and how confident and competent the 
facilitators felt delivering the session components.  Facilitators will also be asked to 
record reasons for any components not being fully delivered.  Different checklists will 
be developed for each session. Due to the dynamic nature of the intervention and 
curriculum development it is not possible to provide definitive and finalised versions of 
these checklists at this time: the checklists will be finalised following the coding of the 
final version of DAFNEplus2. 
 
Procedure 
Facilitators will be asked to complete the checklist at the end of each session where 
possible, or by the end of each day.  They will forward completed checklists to Sheffield 
University CTRU by the end of each day.  Facilitators will rate the extent to which they 
feel they delivered the intervention components listed in the checklists, from 0 (not at 
all), 1 (partially) to 2 (fully delivered). 
 
Analysis 
The proportion of intended components rated as partially/fully delivered by the 
facilitators will be calculated. The same criteria will be applied to classify extent of 
fidelity as in the observed measurements:  if < 50% of intended content is delivered 
                                                             
2
 We are submitting specimen checklists with this revised version of the protocol, these checklists are subject to change as 
detailed above. The curriculum will be subject to change up until the point of recruitment and even after this point there might be 
minor changes which would require modification of the fidelity checklists. A requirement to submit these checklists after each 
change would be a major burden on both the ethics committee and the research team and therefore we seek permission to revise 
checklists without further approval and will not submit additional checklists unless requested to do so.  
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this will be classified as ‘low’ fidelity; 51-79% as ‘moderate’ fidelity, and 80-100%’ as 
‘high fidelity’. Variation in proportion of fidelity of delivery will be examined across: 
session types, facilitators, and courses. 
 
There are well documented discrepancies between what healthcare providers report 
delivering and actually deliver [21]. Therefore, for the DAFNEplus courses where 
session transcripts have also been coded (as described above), self-reported and 
objectively verified practice will be directly compared in terms of the proportion of BCTs 
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Supplementary material 3 – Protocol for DAFNEplus Economic Evaluation 
 
Aims and perspective 
 
We will complete an economic evaluation as part of the study so that we are able to 
understand the cost-effectiveness of DAFNEplus compared to the standard DAFNE 
programme. The economic evaluation will follow guidance set by the National Institute 
for Health and Clinical Excellence for its Technology Appraisal process [1]. The 
analysis will take an NHS and personal social services perspective, measure health 
effects in quality adjusted life years (QALYs), discount future outcomes at 3.5% per 
annum and consider effects and costs over a lifetime time horizon. The primary 
analysis will be use long-term cost-effectiveness modelling, a secondary analysis will 
be an economic evaluation alongside the clinical trial (EEACT). The analysis 
population for all health economic analyses will consist of all participants in the 
DAFNEplus trial. A full Health Economic and Decision Modelling Analysis Plan 
(HEDMAP) will be written and circulated to the Trial Management Group and 
Programme Steering Committee before being signed-off. 
 
Long-term cost-effectiveness modelling 
 
In the long-term modelling exercise, the resulting evidence base will be incorporated 
into an updated Sheffield T1D Diabetes Policy Model [2]. This model has been used 
extensively in the evaluation of education and psychological interventions for people 
with T1D[3–6]. The time horizon of this analysis will be over each simulated individual’s 
lifetime. As such, the long-term modelling will be considered as the primary health 
economic analysis. Demographic variables and some key resource use data (e.g. 
insulin use, contacts with NHS professionals) will be obtained from the trial data. The 
Sheffield T1D Diabetes Policy Model will be updated to use statistical models that 
estimate the clinical effects of DAFNEplus compared to DAFNE on HbA1c, the 
incidence of severe hypoglycaemia and the incidence of DKA. Two long-term 
modelling analyses will be conducted, the first will use the data collected by the one-
year time point and will be submitted as part of the report to the NIHR on the 
DAFNEplus programme grant. This analysis will be updated after the two-year data 
collection is complete to incorporate the statistical analysis of the two-year follow up 
data. These statistical analyses of the clinical effects of DAFNEplus compared to 
DAFNE will be pre-specified in either the statistical analysis plan or the HEDMAP. The 
reporting of this evaluation will follow the Palmer et al[7] checklist for the reporting of 
model inputs to diabetes health economic studies. 
 
Economic evaluation alongside the clinical trial 
 
For the EEACT, we conduct the analysis in line with Ramsey et al’s [8] 
recommendations for cost-effectiveness analysis alongside clinical trials. Specifically, 
we will collect data alongside the trial on intervention costs, associated healthcare 
resource use and a preference based utility measure: the EQ-5D-5L measure [9]. The 
intervention costing process will include training of educators, resource use, and 
adherence to structured follow up appointments, professional staff time and the 
technology component. A standard self-reported resource use questionnaire, used 
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previously in the DAFNEplus pilot (as well as the 5x1 DAFNE [10] and the REPOSE 
trials [11]), will ascertain NHS usage in terms of GP, community, outpatient, A&E and 
inpatients, as well as occurrence of DKA and hypoglycaemic events by level of 
severity. Unit costs will be taken from standard sources (NHS Reference Costs, British 
National Formulary, PSSRU). The standard self-reported resource use questionnaire 
and the EQ-5D-5L will be collected at baseline, 6 months and 12 months. Course costs 
(administrative and clinical) will be estimated using a bespoke questionnaire for 
completion by site staff. Our primary analysis will use the EQ-5D-5L valuation study to 
generate utility scores at baseline, course completion, 6 months and 12 months for 
each study participant [12]. There are on-going discussions about the valuation of the 
EQ-5D-5L, and NICE recently produced a position statement recommending that EQ-
5D-5L data should be valued using mapping to the EQ-5D-3L and not the bespoke 
EQ-5D-5L value set [13,14]. Therefore our primary analysis will follow the most recent 
NICE guidance at the time of analysis, with the other valuation method been used in 
a sensitivity analysis. QALYs for each participant will be estimated by calculating the 
area under the curve defined by EQ-5D utility score, mortality and length of follow-up.  
The base case analysis will use the complete case data. In a scenario analysis, the 
missing data will be imputed. The time horizon of this analysis will be limited to the 
one-year time horizon of the trial. This evaluation will be considered as the secondary 
health economic analysis for two reasons: 1) The effects and costs of DAFNEplus may 
be incurred beyond the one-year trial time horizon (due to expected differences in the 
time to onset of diabetes related complications and potential maintenance of treatment 
effects beyond the trial period); and, 2) the DAFNEplus trial is not powered to detect 
differences in the incidence of long-term diabetes complications, as such the estimates 
of differences in the cost and QALYs between the two trial arms may be misleading. 
 
Outcome measures and uncertainty analyses 
 
In both the EEACT and the long term modelling the main outcome of interest will be 
the comparison of the incremental cost-effectiveness ratio (ICER) of DAFNEplus 
compared to DAFNE. The ICER will be compared to a maximum acceptable ICER of 
£20,000 per QALY gained, as this is the lower limit of the ICER range used by NICE 
to determine if an intervention is cost-effective [1]. Uncertainty in the ICER will be 
determined using: scenario analyses, subgroup analyses (pre-specified with the wider 
DAFNEplus team), probabilistic sensitivity analysis and expected value of information 
calculations. In particular, uncertainty in the cost-effectiveness of DAFNEplus as used 
in a wider rollout (compared to as utilised in the trial) and in subgroups of participants 
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Supplementary material 4 – Development and modification of questionnaires 
and individual items 
 
Confidence in Diabetes Scale (CIDS) 
 
This scale assesses the extent to which an individual believes they can engage in 
particular behaviours related to their type 1 diabetes treatment regimen (self-efficacy). 
The scale was published in 2003 and Dr Cooke contacted Prof Snoek, the senior 
author on the original validation paper to seek permission to amend item 3 on the scale 
(I believe I can perform the prescribed number of daily insulin injections). He gave his 
permission for the team to make the following amendment to reflect the more flexible 
approach to multiple daily insulin treatment regimens, advocated by courses like 
DAFNE and DAFNEplus (I believe I can perform the number of daily insulin injections 
I need to).  
 
Self-Regulation Questionnaire for Type 1 Diabetes (SRQ-T1D) 
 
This questionnaire is an adaptation of the Self-Regulation Questionnaire [1]. Self-
regulation is the ability to develop, implement, and flexibly maintain planned behaviour 
in order to achieve one's goals. The SRQ and our adaptation of this builds on the work 
of Frederick Kanfer and two researchers who formulated a seven-step model of self-
regulation [2,3]. Although this model was developed specifically to study addictive 
behaviours, the self-regulatory processes it describes are meant to be general 
principles of behavioural self-control. In this model, people may have problems 
managing certain behaviours (behavioural self-regulation) because of challenges at 
any of these seven steps: 
 
1. Receiving relevant information 
2. Evaluating the information and comparing it to norms 
3. Triggering change 
4. Searching for options 
5. Formulating a plan 
6. Implementing the plan 
7. Assessing the plan's effectiveness (which recycles to steps 1 and 2) 
 
The original SRQ has demonstrated reliability, concurrent and discriminant validity in 
community samples[4]. It consists of 63 items which was too long for our team to use 
in the DAFNEplus questionnaire pack, when this is one of several process measures. 
This measure was reviewed by 3 members from the DAFNEplus PPI group and by our 
process evaluation team consisting of clinicians, behavioural scientists, psychologists 
and social anthropologists, two of whom also have type 1 diabetes. The PPI group 
strongly recommended altering the wording of the individual items slightly so that these 
were all framed to be diabetes-specific in focus, rather than generic. Dr Cooke, in 
discussion with two members of the PPI group amended the wording of some of these 
items to ensure that they were clear and made sense. The process evaluation team 
and PPI group selected their top 2-3 items from each of the seven categories (above), 
rank ordering them. Dr Cooke then reviewed these to select the items from each 
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category which the majority had agreed should be included within the final 
questionnaire.  
 
Beliefs about Consequences of Diabetes Self-Care Behaviours; Diabetes 
Support and Routines 
 
The DAFNEplus revisions to the original DAFNE curriculum were structured around 
the Theoretical Domains Framework[5] hence it is very important to the process 
evaluation team to assess the constructs that are being targeted within individuals 
through the content and delivery of the DAFNEplus course; to assess whether 
participants in the DAFNEplus and standard DAFNE groups respond differently on 
these measures but also whether these constructs explain any differences in 
outcomes (HbA1c and diabetes-specific quality of life). Three of these constructs are 
‘social influences’, ‘beliefs about consequences of diabetes self-care’ and 
‘environmental cues and prompts’. The research team have generated 11 diabetes-
specific items to assess these constructs and have piloted them with our PPI group. 
These are unvalidated but once we have collected data at two timepoints (course 
completion and 3-months follow-up), if these measures are shown not to be 
psychometrically robust, we will remove these items from the 9-month follow-up point. 
Please note that we are only collecting these process measures at 3 timepoints.   
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List of Abbreviations and Definitions of Terms 
ADDQoL-14 Audit of Diabetes Dependent Quality of Life (14 items) 
AE Adverse Event 
BMI Body Mass Index 
CIDS Confidence in Diabetes Scale 
CRF Case Report Form 
CTRU Clinical Trials Research Unit 
DAFNE Dose Adjustment For Normal Eating 
DIDP DAWN Impact of Diabetes Profile 
DKA Diabetic Ketoacidosis 
DME-Q Diabetes Management Experience Questionnaire 
DSRQ Diabetes Strengths and Resilience Questionnaire 
eGFR Estimated Glomerular Filtration Rate 
EQ-5D-5L EuroQol - 5 Dimensions - 5 Levels 
GCP Good Clinical Practice 
GLM Generalised Linear Model 
HASMID Health And Self-Management In Diabetes 
HbA1c Glycated Haemoglobin (Haemoglobin A1c) 
HCS Hypoglycaemia Confidence Scale 
HDL High-Density Lipoprotein  
HFS Hypoglycaemia Fear Survey 
ICC Intra-class Correlation Coefficient 
IQR Inter Quartile Range 
IRR Incidence Rate Ratio 
ISRCTN International Standard Randomised Controlled Trial Number 
ITT Intention To Treat 
LDL Low-Density Lipoprotein  
LRT Likelihood Ratio Test 
MD Mean Difference 
MDI Multiple Daily Injections 
NHS National Health Service 
OR Odds Ratio 
PAID Problem Areas In Diabetes 
PP Per Protocol 
QoL Quality of Life 
RCT Randomised Controlled Trial 
REC Research Ethics Committee 
SAE Serious Adverse Event 
SCB-T1D Self-Care Behaviours: Type 1 Diabetes 
SD Standard Deviation 
SOP Standard Operating Procedure 
SRQ-T1D Self-Regulation Questionnaire 
SUS System Usability Score 
T1D Type 1 Diabetes 
TMG Trial Management Group 
TSC Trial Steering Committee 
VAS Visual Analogue Scale 
W-BQ28 Well-Being Questionnaire 28 
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1 INTRODUCTION 
1.1 Background and Rationale 
The successful management of Type 1 Diabetes (T1D) requires those affected (>300,000 adults in the 
UK) [1] to keep their glucose levels sufficiently close to normal to avoid long-term complications [2]. 
In this condition, unlike type 2 diabetes, there is an absolute insulin deficiency, and so insulin must be 
injected subcutaneously, and tablet therapy is not possible. Preventing complications depends upon 
an individual’s ability to prevent hyperglycaemia (high blood glucose levels) by self-managing their 
condition. This is done by calculating precise insulin doses based on accurate estimations of food 
intake before every meal using frequent blood glucose measurements, and accounting for fluctuations 
in physical activity, illness, stress and hormones. Hypoglycaemia (low blood glucose levels), if severe, 
can result in acute cognitive impairment, confusion, collapse and injury, coma or even death [3].  
 
Dose Adjustment For Normal Eating (DAFNE) is a clinical education programme run within the National 
Health Service (NHS), designed to teach and improve self-management skills in flexible intensive 
insulin therapy to improve both glucose control and quality of life in adults with T1D.  It is a five-day 
training course for adults with T1D, delivered in small groups. The DAFNEplus programme grant has 
modified the existing DAFNE curriculum to incorporate techniques for initiating and sustaining 
behaviour change, structured follow-up support, and digital information communication technology.  
 
1.2 Objectives  
The primary objective of the trial is to:  
1. Assess the effects of the intervention on glycaemic control as measured by glycated 
haemoglobin (HbA1c) at 12 months. 
 
The secondary objectives of the trial are to:  
1. Assess the medium term effect of the intervention on glycaemic control, as measured by 
HbA1c, using data at 6 months, 
2. Assess the effects of the intervention on the diabetes-specific quality of life, 
3. Assess the effects of the intervention on diabetes distress and other biomedical outcomes 
(severe episodes of hypoglycaemia, diabetic ketoacidosis, weight, body mass index, blood 
pressure and lipids), 
4. Undertake a mixed methods process evaluation to aid understanding of the Randomised 
Controlled Trial (RCT) findings, and to inform decision making about the implementation of 
DAFNEplus in clinical care post-trial, 
5. Assess fidelity of delivery of the DAFNEplus intervention, 
6. Undertake a health economic analysis to determine the cost-effectiveness of DAFNEplus 
versus standard DAFNE. 
Objectives 4, 5 and 6 under secondary objectives will not be considered as part of this SAP and will be 
dealt with separately to the main trial analysis. 
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2 TRIAL METHODS  
2.1 Trial Design  
The trial will use a pragmatic, parallel group, cluster randomised (1:1 allocation) controlled design 
involving 14 sites. Centre randomisation is required rather than individual since ‘contamination’ of the 
control arm may occur if educators are trained in DAFNEplus (intervention) and still are required to 
deliver standard DAFNE (control) [4]. Potential participants are identified by local diabetes clinicians 
and will use standard criteria for referral to DAFNE.  
 
Participants recruited at control centres will receive treatment as usual and will attend the DAFNE 
course one day a week, over five consecutive weeks. A bolus calculator will be provided to support 
the calculation of insulin dose, but there will be no structured follow-up appointment beyond those 
provided in usual care. 
 
Participants in centres allocated to the intervention will attend the DAFNEplus course one day a week, 
over five consecutive weeks, which includes the use of technology to transmit and display blood 
glucose data to support pattern recognition and interpretation. A bolus calculator to support insulin 
dose calculations will be provided and up to five structured follow-up appointments are offered in the 
12 months after the course.  
 
Further details on the trial design can be found in the protocol.  
 
2.2 Randomisation and Blinding  
Following ethical approval, all participating centres were randomised on a 1:1 basis to control 
(standard DAFNE courses) or the intervention arm (DAFNEplus course). In order to balance the centres 
within the two arms, a covariate constrained approach [5] was adopted matching the centres on the 
number of patients, number of educators and the total number of previous DAFNE courses delivered 
by the centre as stratification variables. Due to the nature of the intervention, The University of 
Sheffield Clinical Trials Research Unit (CTRU) in-house randomisation system (SCRAM) was not 
applicable and so in line with Standard Operating Procedure (SOP) ST007, a randomisation guidance 
document detailing the randomisation procedure has been written. The random allocation was 
conducted by the trial statistician using STATA [6] and therefore no outcome data which is split by 
treatment group will be seen by the statistician until the trial is complete to minimise bias. Further 
details on the randomisation and unblinding can be found in the protocol.  
  
2.3 Sample Size 
2.3.1 Original Sample Size 
It is expected that there will be 882 patients referred for DAFNE courses within the 15-month 
recruitment window and of these, it is expected that 75% (662 patients) will be recruited, equivalent 
to 47 participants at each of the 14 centres. Based on data from current DAFNE courses, a further 25% 
are expected not to meet the primary analysis population criteria of a baseline HbA1c greater than 
7.5%, leaving 497 participants. Finally, we anticipate 15% of participants to be lost to follow-up by the 
12-month stage, therefore giving a primary analysis population of 422 patients. Taking into account a 
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design effect, due to the cluster design of the trial, with an Intra-class Correlation Coefficient (ICC) of 
1.5% (from previous DAFNE data) and 30 patients per cluster (422 patients over 14 centres) the design 
effect is 1.435 leaving the effective total sample size of 294 participants (147 per arm). 
 
Using a two-sample comparison of mean HbA1c at the 12-month follow-up with 2-sided alpha of 5%, 
a correlation of 0.5 between baseline and final values and a standard deviation of 1.45 (from previous 
DAFNE data), the trial sample gives 92% power to detect a 0.5% difference in HbA1c between the two 
treatment groups. 
 
2.3.2 Updated Sample Size 
The original calculations (i.e. worked backwards from the expected number of recruits) gave a power 
of 92.7%. The team discussed different options, but in light of the difficulties in enlisting new centres 
and therefore now 13 centres not 14, it was agreed by our Trial Steering Committee to continue with 
the original planned recruitment per centre, with 6 interventions and 7 control. Therefore, reducing 
the sample size solely in the intervention arm. This results in a power of 90.4% with a small imbalance 
between the two arms (ratio 1:1.67) with a reduced sample size of 615 (instead of 662). As this trial is 
cluster randomised and provided through courses, there was always likely to be some imbalance 
between the two treatment arms which is out of our control.  
 
2.4 Trial Framework 
The primary aim of this trial is to conduct a superiority cluster RCT comparing the new DAFNEplus 
intervention to the existing DAFNE to detect a minimum clinically significant difference of 0.5% in 
HbA1c between the two groups after 12 months.  
 
2.5 Trial Monitoring and Management 
In compliance with Sheffield CTRU’s SOPs, the following committees will be established to govern the 
overall conduct and supervision of the trial: 
 Trial Steering Committee (TSC) 
 Trial Management Group (TMG) 
 
The trial will be supervised on a day to day basis at Sheffield CTRU by the Trial Manager with 
supervision from the Chief Investigator and a Senior Trial Manager.  
 
2.6 Interim Analysis and Stopping Rules  
There are no interim analyses or early stopping planned for this trial, hence no stopping rules are 
applicable. 
 
2.7 Timing of Final Analysis 
The final analysis will take place after the last participants have completed their 12-month follow-up 
visit. All data will be analysed collectively at this time point. A further study will be completed in the 
future to complete analysis of data collected at the 24-month follow-up, but this is not included within 
this SAP and will be outlined separately.  
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2.8 Timing of Outcome Assessments  
Table 1 below shows the biomedical and psychological outcome measures and the different time-








Table 1: Outcomes measures within the trial and time points they will be collected at 
Outcome Measure Baseline 
6 Months Post 
Course 
12 Months  
Post Course 
Clinical Outcomes 
Demographics1  x   
HbA1c x x X 
Severe Hypoglycaemic Episodes x x x 
Diabetic Ketoacidosis (DKA) Episodes x x x 
Body Mass Index (BMI) x x x 
Blood Pressure x  x 
Lipids (HDL, LDL)2 x  x 
Psychological Outcomes 
ADDQoL-15 (Diabetes-specific quality of 
life) 
x x x 
DIDP (Diabetes-specific quality of life) x x x 
PAID-11 (Diabetes Distress) x x x 
W-BQ28 (Diabetes-Specific Wellbeing) x x x 
HFS-11 (Fear of Hypoglycaemia) x x x 
Gold Score (Hypoglycaemia awareness)  x x x 
Health Economic Measures 
HASMID (Health Status) x x x 
EQ-5D-5L (Health Status) x x x 
Process Measures 
DSRQ x   
SCB-T1D x   
Usability Score    
DME-Q x   
HCS x   
Beliefs about Consequences x   
SRQ-T1D x   
1: Detail description of demographic characteristics are found under section 4.4 
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2: HDL=High Density Lipoprotein, LDL=Low Density Lipoprotein  
 
3 STATISTICAL PRINCIPLES 
This statistical analysis plan (SAP) is written in conjunction with the International Conference of 
Harmonisation topic E9 [7], applicable Standard Operating Procedures (SOP) from the Sheffield Clinical 
Trials Research Unit (CTRU) (ST001 and ST006).   
 
3.1 Confidence Intervals and P Values 
All statistical tests will be completed at the 5% significance level and estimates of the treatment effect 
will be reported with their associated 95% confidence intervals. All tests completed will be two-sided. 
The results of the trial are focussed on the primary endpoint (HbA1c at 12 months) so adjustment for 
multiple testing and control of the type 1 error rate is required.  
 
3.2 Adherence and Protocol Deviations 
Adherence to the standard DAFNE course within the control group is defined as: 
 Attending a minimum of four of the five days within the course which must include the first 
two days. 
Adherence to the DAFNEplus course within the intervention group is defined as: 
 Attending a minimum of four of the five days within the course which must include the first 
two days AND 
 Attending at least three of the five follow-up sessions (this can be any three sessions) 
 
Adherence to the courses will be presented as the number and percentage of participants in each arm 
of those that adhered. Additionally, for the intervention group the number and percentage of 
participants that adhered to each of the two adherence requirements will be presented separately to 
show which, if either, of these are more prominent.   
 
In the DAFNEplus trial, any intended failure to adhere to the protocol will be classed as protocol 
violation and may be minor or major while any unintended (non-serious) departures from the protocol 
would be considered as protocol deviations and all these will be reported. 
 
Attendance will be captured on case report forms (CRFs) when participants attend the course. 
Participants who failed to meet this criterion will be classed as having a major protocol deviation. 
 
The number (and percentage) of patients with major and minor protocol deviations will be 
summarised by treatment group with details of type of deviation provided. No formal statistical 
testing will be undertaken between the two groups.  
 
3.3 Analysis Populations  
The primary analysis set will be that defined in Intention To Treat (ITT) on the primary outcome. 
Additional analysis populations, such as Per Protocol (PP), will be used as sensitivity analyses. Table 2 
defines each of the analysis sets. 
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Table 2 Definition of the analysis set 
Analysis Set Outcomes Participant Inclusion Criteria 
Primary ITT 





All consented participants, analysed according to their 
centre’s randomisation regardless of their adherence to the 
entry criteria, intervention received, subsequent 
withdrawal or deviation from the protocol unless they have 
explicitly requested that their data be removed [7]. In 
addition, participants must have a baseline HbA1c more 
than 7.5%. 
Full ITT Secondary outcomes 
and as a sensitivity 
analysis for the 
primary outcome 
All consented participants, analysed according to their 
centre’s randomisation regardless of their adherence to the 
entry criteria, intervention received, subsequent 
withdrawal or deviation from the protocol unless they have 





All consented participants excluding those who didn’t 
adhere to the assigned intervention as defined by section 
3.2. 
 
4 SCREENING, RECRUITMENT, DEMOGRAPHICS AND WITHDRAWAL 
4.1 Eligibility Criteria 
Centre eligibility: 
 Adult diabetes centre currently delivering DAFNE 
 At least three DAFNE educators trained in delivering the five-week model of DAFNE 
 Delivery of sufficient DAFNE courses per year to recruit the trial sample. 
 
Participant eligibility: 
Inclusion and exclusion criteria for participants are outlined in Table 3. 
 
Table 3: Patient eligibility criteria 
Inclusion Criteria Exclusion Criteria 
Age ≥18 years HbA1c >12% 
 
Diagnosis of type 1 diabetes for ≥6 months or 
post-honeymoon 
Current use of continuous subcutaneous insulin 
infusion (CSII) pump therapy 
Prepared to undertake multiple daily injections 
(MDI) therapy and frequent self-monitoring of 
blood glucose 
Serious diabetes-related complications (e.g. 
blindness, renal dialysis), or other serious co-
morbidities (e.g. psychosis, diagnosed eating 
disorder) 
Available to attend all sessions Unable to hear/speak/understand/read/write in 
English 
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Investigator has confidence that the patient is 
capable of adhering to all the trial protocol 
requirements 
Previous participation in standard DAFNE course 
less than 5 years before proposed trial 
enrolment date 
 Unable to give informed consent. 
 
4.2 CONSORT 
Using guidelines from the CONSORT statement [8], the summaries outlined Table 4 will be calculated 
in order to construct a CONSORT flowchart. Data will be presented overall and by treatment arm to 
show if any differences are present due to the sites treatment allocation.  
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Table 4: CONSORT Summary 
Screening Data   Number of participants assessed for eligibility at screening 
 Number ineligible including reasons 
 Number eligible but declined to participate including reasons 
Recruitment Data  Number of participants consented and recruited 
 Number and percentage of those who attended all five sessions within 
either DAFNE/DAFNEplus course 
 Number and percentage of those who completed the primary outcome 
(HbA1c) at 6 and 12 months follow-up 
Lost to Follow 
Up/Withdrawal 
Data 
 Number and percentage of those consented who dropped out and 
withdrew before the course 
 Number and percentage of those consented who dropped out and 
withdrew after completing the course but before the 6-month follow-up 
 Number and percentage of those consented who dropped out and 




 Number of those included in primary ITT set at 6 and 12 months follow-
up 
 Number of those included in full ITT set at 6 and 12 months follow-up 
 Number of those included in PP set at 12 months follow-up 
 
4.3 Withdrawal of Participants  
Details of potential reasons for withdrawal are found in the protocol and summaries of these reasons 
plus any additional reasons found within the trial will be presented overall and split by treatment arm. 
Withdrawal numbers will also be summarised dependent on if the participant has withdrawn from the 
intervention, but continue with follow-up, withdrawal from follow-up but allow data collected to date 
to be used, withdrawal for all data collected to date to be used, or lost to follow up.  
 
4.4 Baseline Characteristics 
Baseline characteristics will be summarised at both the centre and participant level to assess the 
balance between the two treatment arms.  
 
At the centre level, the stratification variables used (number of patients, number of educators and the 
total number of previous DAFNE courses delivered) within the randomisation will be presented by 
treatment arm to evaluate the balance between centres.  
 
At the participant level, the variables shown in Table 5 as captured at baseline will be presented overall 
and by treatment arm. Categorical variables will be presented using counts and percentages, 
continuous variables will be presented with means and standard deviations or median and inter-
quartile ranges as appropriate. No statistical significance testing will be used to test baseline 
imbalances between the two groups but any noteworthy differences will be descriptively reported.  
 
Table 5: Baseline variables 
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Demographics 
 Age (Years) 
 Gender 
 Ethnicity 
 Highest qualification 
Medical History 
 Duration of diabetes (Years) 
 Previously attended a DAFNE course 
 Pregnancy since diabetes 
 Current pregnancy, if yes gestation (weeks) 
 Use of lipid lowering medication 
 Use of antiplatelet agent 
 Use of medication for depression 
 Smoking status, if yes no of cigarettes per day 
 Physical activity levels 
 Complications – conditions and events (list as applicable) 
 Quick acting insulin (average daily dose, number of injections per day and type) 
 Background insulin (average daily dose, number of injections per day and type) 
 Pre-mixed insulin (average daily dose, number of injections per day and type) 
 Use of ratios 
 Presence of Lipohypertrophy 
 Number of blood glucose test performed (last 2 weeks) 
 Use of CGM, method and length of use (for Libre only – how it is funded and how it’s being 
used) 
 Use of apps 
 Severe hypoglycaemic episode in the last year 
 Number of hypoglycaemic episodes that were unable to be treated themselves 
 Number of hypoglycaemic episodes that required paramedic assistance 
 Number of hypoglycaemic episodes that required A&E attendance 
 Number of hypoglycaemic episodes that required hospital admission 
 Blood glucose of hypoglycaemia 
 Admissions due to DKA (ever and in last year) 
Labs and Vital Signs 
 BMI (kg/m2) 
 Blood pressure (mmHg) 
 HbA1c (mmol/mol) 
 Creatinine (µmol/L) 
 Albumin-creatinine (mg/mmol) 
 Cholesterol (mmol/L) 
 Triglycerides (mmol/L) 
 High Density Lipoprotein (HDL) cholesterol (mmol/L) 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-040438:e040438. 11 2021;BMJ Open, et al. Coates E
DAFNEplus Statistical Analysis Plan  
Version 1 17th December 2019 
 
Page 13 of 22 
If there are any issues with partial dates in the database, the following approaches will be used to deal 
with them and therefore still allow derived time variables such as duration of diabetes to be calculated 
with sufficient precision: 
  If only year is available ("YYYY"), replace with "01/07/YYYY" or 
  If only month and year are available ("MM/YYYY"), replace with "15/MM/YYYY". 
 
5 OUTLINE OF STATISTICAL ANALYSIS 
Continuous variables will be summarised and presented by treatment group and overall as follows: 
a) Mean and standard deviation (SD) for normal distribution 
b) Median, Inter-Quartile Range (IQR), minimum and maximum for asymmetrical distribution 
Categorical variables will be summarised and presented by treatment groups as the number of 
observations and proportion in each category and overall. 
 
5.1 Outcome Measures 
5.1.1 Primary Outcome 
The primary outcome is glycaemic control defined as HbA1c, the primary endpoint refers to this data 
at 12-months but this will also be collected at baseline and 6-months (secondary endpoint). HbA1c is 
collected in mmol/mol but will be presented as a percentage. In order to convert between the two, 
the following calculation will be used [30]: 
HbA1c (%) = HbA1c (mmol/mol)/10.929 + 2.15 
 
5.1.2 Secondary Outcomes - Biomedical 
As an extension to the primary outcome, a secondary binary outcome to represent successful 
glycaemic control [9] will be calculated using the HbA1c data at 6- and 12-months. This outcome 
identified whether a participant achieved either a:  
1) HbA1c <7.5% (58 mmol/mol) or  
2) Reduction in HbA1c of ≥0.5% (≥5.5 mmol/mol).  
 
Patient’s BMI will be calculated using height and weight data at baseline, 6- and 12-months. Note – 
height is only collected once at baseline and used throughout. Weight can be collected either in 
kilograms (kg) or stones (st) and pounds (lb) and if collected in stone a conversion to kg will be 
completed using the following formula: 
Weight (kg) = Weight (st)/0.15747 + Weight (lb)/2.2046 
Similarly, height can be collected in metres (m) or feet (ft) and inches (in) and the following formula 
will be used to convert all to m: 
Height (m) = Height (ft)/3.2808 + Height (in)/0.0254 
BMI will then be calculated using the following formula: 
BMI (kg/m2) = Weight (kg) / Height (m)2 
 
Episodes of severe hypoglycaemia (as defined by the American Diabetes Association [9]), and 
incidence of DKA will be collected at baseline, 6-months and 12-months. Both will collect the number 
since the last visit. 
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Two different measures of lipids will be presented, high- and low-density lipoprotein which will be 
measured in mmol/L. 
 
5.1.3 Secondary Outcomes - Psychological  
 Audit of Diabetes-Dependent Quality of Life-15 (ADDQoL-15) 
ADDQoL-15 is a questionnaire to measure the impact of diabetes and its treatment on a participant’s 
QoL [10], [11]. It contains two overview items and 15 diabetes-specific items that relate to different 
aspects of life. Each has two parts, an impact score and an importance score. Each impact score is 
scored from -3 (very much better) to 1 (worse) and each importance score is from 3 (very important) 
to 0 (not at all important). These are then multiplied together to get a weighted impact score for each 
domain with -9 representing the maximum negative impact and 3 being the maximum positive impact. 
The average weighted impact (AWI) is then calculated as a mean of the weighted impacts for each 
domain.  
 
If either the impact score or the importance score is missing, then the domain score cannot be 
computed and will not be included within the AWI. In the first instance, an AWI will only be calculated 
is all domain scores are available.  
 
 DAWN Impact of Diabetes Profile (DIDP) 
The participant’s diabetes-specific quality of life will be assessed using the DIDP [12]. This consists of 
seven-items which investigates the impact diabetes has on different aspects of the participant’s life. 
Each item is scored from 1 (very positive impact) to 7 (very negative impact), the composite score is 
the mean of all available responses, it ranges from 1-7 with lower scores indicating a greater positive 
impact. The percentage score is the composite score divided by 7, again lower percentages indicate 
greater positive impact. 
 
 The Problem Areas in Diabetes 
The Problem Areas in Diabetes (PAID) [13], [14] is a self-reported questionnaire that describe negative 
emotions related to diabetes (e.g. fear, anger, frustration) to assess diabetes distress. The short 
version, which will be used in this trial, consists of 11 items. Each question has five possible answers 
with a value from 0 to 4, with 0 representing “no problem” and 4 “a serious problem”. The overall 
score is the sum of all questions and ranges from 0 (best) to 44 (worst). A score of 18+ indicates severe 
diabetes distress. 
 
 Diabetes-specific Positive Well-being 
Diabetes-Specific Positive Well-being will be measured using the specific subscale of the Well Being 
Questionnaire (W-BQ28) [15]. This questionnaire consist of four subscales each with four possible 
responses used to measure diabetes-specific well-being. Each item is scored from 0 (not at all) to 3 (all 
the time). The scores for this subscale are summed to get a total score ranging from 0-12 with higher 
scores representing more positive well-being.   
 
 Fear of hypoglycaemia (HFS-II Short Form) 
This 11-item questionnaire assesses the level of fear amongst people with diabetes [16] and contains 
five behavioural items and six worry items taken from the original full measure. Each item is scored 
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on a five-point Likert scale (0=never to 4=almost always) and a total score for the behaviour and worry 
subscales are calculated by summing the scores.  
For missing values on the questionnaire, participant mean score will be imputed for missing values if 
at least nine of the questions have been completed.  
 
 Health Status. 
Health status will be measured using EQ-5D-5L [17] questionnaire which is a self-reported outcome 
measure which aims to assess the general health-related quality of life of the participant. It consists 
of five dimensions measure mobility, self-care, usual activity, pain/discomfort and anxiety/depression 
with each dimension having five possible responses. Participants also rate their overall health on the 
day of the interview on a 0–100 visual analogue scale with 0 = worst imaginable health state and 100 
= best imaginable health state.  
 
Scoring of EQ-5D-5L will be either scored using the relevant value set [18] or by mapping onto the EQ-
5D-3L depending on the most up to date method at the time. The EQ-5D-5L health utility will not be 
calculated if any of the five dimensions are missing. 
 
 Health and Self-Management in Diabetes  
Health status will also be assessed using HASMID [19] assessment tool. It consists of ten items each 
with four possible responses. Responses are scored from zero to three with higher scores indicating 
little or no impact upon health related QoL. The overall questionnaire is a sum of all question scores 
and scored from 0 to 30 with higher scores indicating good health related QoL and a lower score 
indicating poor health-related quality of life.  The scores are then used to calculate utility scores, the 
HASMiD health utility will not be calculated if any of the component ten questions are missing. 
 
 Hypoglycaemia awareness 
Awareness of hypoglycaemia will be measured using the Gold score questionnaire [20] which is a 1 
item questionnaire consisting of a seven-point scale where one represent ‘always aware of the onset 
of hypoglycaemia’ and seven ‘never aware of the onset of hypoglycaemia’.  
 
5.1.4 Secondary Outcomes - Process Measures 
 Diabetes Strengths and Resilience Questionnaire (DSRQ) 
Adaptive behaviours and attitudes associated with overcoming challenges with diabetes management 
will be measured using the DSRQ [21]. The questionnaire consists of 12 items each scored from 1 
(Never) to 5 (Always), the scores are summed to produce the total score which ranges from 12-60. 
Higher scores indicate perception of having greater T1D strengths. 
 
 Self-Care Behaviours: Type 1 Diabetes (SCB-T1D) 
Fifty items from the Self-Care Behaviours: Type 1 Diabetes (SCB-T1D) scale [22]will be used to assess 
the extent to which participants engaged with diabetes self-care behaviours. If an individual has 
completed over 50% of the items then the mean of the completed items will be used for the missing 
items. Otherwise the score will be coded as missing. 
 
 System Usability Score (SUS) 
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The System Usability Score (SUS) [23] will be used to gather feedback on the DAFNEplus website at 
follow-up. As recommended by the scale authors the term ‘system’ will be replaced with 
‘Glucocollector’ for the DAFNEplus group and ‘bolus calculator’ for the DAFNE (control) group. The 
SUS consists of 10 questions scored from 1 (strongly disagree) to 5 (strongly agree). Before calculating 
the total score the individual scores are transformed as follows: 
 For each odd question (1,3,5,7 and 9) subtract 1 
 For each even question (2,4,6,8 and 10) subtract from 5 
The total score is the sum of these transformed values multiplied by 2.5, the score ranges from 1-100 
with higher values indicating better usability. 
 
 Diabetes Management Experience Questionnaire (DME-Q) 
Satisfaction with diabetes treatment will be measured using the Diabetes Management Experience 
Questionnaire (DME-Q). 
 
 Confidence in Diabetes Scale (CIDS) 
The Confidence in Diabetes Scale (CIDS) [24] is a self-reported questionnaire with 20 items each scored 
from 1 (No, I am sure I cannot) to 5 (Yes, I am sure I can). The overall score is the sum of the items, 
minus the lowest possible score (20), divided by the score range (80) and multiplied by 100. This results 
in a 0-100 scale where higher scores indicate higher self-efficacy. 
 
 Hypoglycaemia Confidence Scale (HCS) 
The Hypoglycaemia Confidence Scale (HCS) [25] consists of 9 questions (8 items for participants 
without a partner) each rated from 1 (Not confident at all) to 4 (Very confident). The total score is 
calculated as the sum of the items divided by the number of items completed and ranges between 1-
4 with higher scores indicating more confidence. 
 
 Beliefs about Consequences 
The Beliefs about Consequences questionnaire contains 6 items scored from 1 (not at all helpful) to 5 
(extremely helpful), the items are summed to obtain the total score which ranges from 6-30. 
 
 Self-Regulation Questionnaire (SRQ-T1D) 
The SRQ-T1D questionnaire is an adaptation of the Self-Regulation Questionnaire [26], individual 
items are scored from 1 (strongly disagree) to 5 (strongly agree) and some items are reverse scaled 
(i.e. 1=5, 2=4, 3=3, 4=2, 5=1). 
 
5.2 Analysis of Primary Outcome 
The primary analysis will use the primary outcome of HbA1c at 12-months, using the primary ITT 
analysis population which is all consenting participants that have a baseline HbA1c > 7.5%. Descriptive 
statistics for baseline, 6- and 12-month HbA1c will be summarised and presented as mean, standard 
deviation (SD), median, min and max.  
 
The treatment groups will be compared using a multiple linear regression model with coefficients 
estimated using GEE. The advantage of using GEE is that it is possible to calculate robust standard 
errors which are consistent even if the correlation structure is specified incorrectly [27], [28]. In this 
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model, an exchangeable correlation will be used to account for the clustering. In the event of any 
baseline differences in patient demographic characteristics, these covariates will be included in the 
model along with course. Adjustments for the stratification variables has not been included as they 
are at the centre level and therefore will be highly correlated with the course variable included in the 
model. The adjusted and unadjusted mean difference (MD) between DAFNE and DAFNEplus with 
associated 95% CI and p-value will be reported as well as the ICC from the model.  
 
5.2.1 Model Checking  
Given that correlation can lead to loss of information, ignoring the correlation structure can waste 
information and decrease standard errors when using an inappropriate analytical method. Model 
assumptions will be assessed graphically using the following methods: 
 The linearity of the response variable will be assessed by a plot of the residuals against each 
explanatory variable in the model (curvilinear relationships). In cases of non-linearity, a 
transformation of the response variable could be performed, e.g log transformation or for 
particular fixed effect, a non-linear transformation of the particular fixed effect could be 
undertaken and included in the model, 
 Constant variance will be assessed by plotting the residuals against the fitted values (errors 
have constant variance), 
 Normality checks will be performed using a normal probability plot of the residuals 
(standardised) or histogram of the residuals, 
 Partial residual plot will be used in identifying if quadratic or higher order terms are needed 
for any of the explanatory variables, 
 Cook’s distance can be used to indicate those observations that may be having an 
undue influence on the estimates. In cases of influential points, a sensitivity analyses with and 
without those points to assess the effects these points have on the regression coefficients will 
be undertaken.  
 
5.3 Sensitivity Analyses of the Primary Outcome  
Matching analyses will be undertaken on the primary outcome at 12-months using the full ITT and PP 
analysis sets as defined in table 4. These analyses will be completed using the primary analysis model 
with the only alternation the population set included within the analysis.  
 
Additionally, a multi-level model will be completed using the primary ITT population on the primary 
outcome. This will contain the variables as mentioned in the original analysis but use course as a 
random effect to take into account the clustering in this model. These analyses will help to assess the 
robustness of the main trial result. The results in each case will be presented as adjusted MD of HbA1c 
at 12 months with associated 95% CI and p-value. 
 
5.4 Subgroup Analyses 
The following sub-group analysis will be completed on an ITT basis (Full ITT analysis population). The 
analysis will be the same model as the primary analysis with the addition of an interaction term 
between the treatment and subgroup to assess the stability of the result in different populations. 
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Treatment effect estimates with 95% confidence intervals will be calculated for each sub-group and a 
test for the overall interaction effect to reduce p-value use within each subgroup.  
a) Previously attended a DAFNE course (Yes, No) 
b) Use CGM or flash glucose monitoring between baseline and 12-month follow up (Yes, No) 
c) Baseline HbA1c (<7.5%, 7.5% < 8.5%, ≥8.5%) 
d) Duration of diabetes (<15 years, ≥15 years) 
e) Blood glucose level that symptoms of hypoglycaemia occur (do not feel symptoms, < 3mmol/l, 
≥ 3mmol/l)  
f) Self-reported use of the bolus advisor over the study duration (never or rarely, sometimes, 
often or always) 
g) Age (<34, 35-49, ≥50 years) 
h) Sex (Male, Female) 
i) BMI (Normal (<25), Overweight (25 < 30), Obese (≥30))  
j) Socio-economic status (SES) as defined by the ONS Index of Multiple Deprivation (4 groups: 
above/below median in England, and above/below median in Scotland) 
k) Total daily dose of insulin at baseline 
l) Experience of lead course educator (Less experienced (6 courses or less within previous 3 
years OR completed the DAFNE educator programme within previous year), More 
experienced (7+ courses within previous 3 years OR had continuous educator status for over 
6 years)) 
m) Pregnant during the trial (Yes, No) 
n) Type of basal insulin: (Human, Levemir, Lantus, Degludec, Toujeo) 
 
5.5 Handling Missing Data 
Missing observations can occur for numerous reasons (e.g. attrition) which can shrink the sample size, 
affects the precision of confidence intervals, reduce statistical power and biases parameter estimates 
[29]. Appropriately dealing with missing observations requires careful examination of data to identify 
the type and pattern of missingness.  
 
In DAFNEplus, we anticipate that missing observations on the primary outcome (HbA1c) at 6 and 
12months will occur amongst ITT participants. HbA1c results will be considered missing if the measure 
is outside +/- six weeks of the expected follow-up date. For the primary endpoint of HbA1c at 12 
months, participant characteristics will be compared for those with and without the outcome. The aim 
of this is to explore any possible predictors of the missing outcome and evaluate the missing at random 
assumption. Multiple imputation strategies using a sequence of regression models [30] on the primary 
endpoint will be used where the missing values are filled ten times to generate ten complete data sets 
while utilising all variables that were included in the primary outcome analysis (section 5.4) as 
predictors. Any additional variables associated with the missing data will be included in the imputation 
model. This model will use a conservative approach by excluding treatment allocation.  
 
If the data results in being missing not at random then a sensitivity analysis will be completed to assess 
the difference this makes on the results. 
 
If weight is not recorded, other time points can be used as follows: 
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 Baseline weight missing - use 6-month weight, 
 6-month weight missing - if both baseline and 12-month weight are available, use the mean 
of these two. If only one of baseline or 12-month data are available, the recorded value will 
be used, 
 All other circumstances - weight defined as missing. 
 
5.6 Analysis of Secondary Outcomes - Biomedical   
5.6.1 HbA1c 
Additional secondary analyses on the primary outcome using the same model described in section 5.4 
will be undertaken using HbA1c data collected at 6 months. This will be undertaken for all participants 
with HbA1C > 7.5% on an ITT basis. The adjusted and unadjusted mean difference (MD) between 
DAFNE and DAFNEplus with associated 95% CI and p-value will be reported as shown in table 7.11. 
Multiple imputations will be undertaken for missing HbA1c at 6 months using model described in 5.7. 
 
The proportion of patients that have achieved improved glycaemic control will also be assessed. The 
patient is deemed to have improved glycaemic control if they achieved either: HbA1c <7.5% (58 
mmol/mol) OR decrease in HbA1c ≥0.5% (≥5.5 mmol/mol). To test this, a GLM using a logit link 
function with treatment group, course and centre as random effects, and any baseline characteristics 
as used within the primary analysis model will be used (Logistic regression). Summary statistics for 
counts and percentages at 6 and 12 months follow up will be reported for DAFNE and DAFNEplus and 
overall.  Treatment effect will be reported as both unadjusted or adjusted Odds Ratio (OR) with its 
associated 95% CI and p-value. This analysis will be undertaken using data collected at 6- and 12-
month follow-up. 
 
Additionally, it is important to assess the HbA1c trend over time.  
 
5.6.2 Weight, BMI, Blood Pressure and Lipids 
Summary statistics will be presented for each of these variables at baseline, and 12-months follow-up 
and all are treated as continuous variables. Summaries of weight and BMI at 6-months will be 
presented in the same way. Results will be presented by treatment group and overall and it will include 
the number, range and either the mean and SD or median and interquartile range depending on the 
distribution.  
 
5.6.3 Severe Hypoglycaemia and DKA 
The total number of episodes of hypoglycaemia will be treated as continuous and summary statistics 
of episodes since their last visit prior to the 12-month follow-up will be reported for DAFNE, DAFNEplus 
and overall. 
 
To test for the difference between the two groups, the number of episodes of severe hypoglycaemia 
will be modelled using a negative binomial regression model with treatment group, baseline HbA1c 
and course (random effect). Treatment effect will be reported as Incidence Rate Ratios (IRR) with its 
associated 95% CI and p-value. 
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An additional analysis will be complete for the proportion of participants who experienced at least 
one episode of severe hypoglycaemia since their last visit prior to the 12 months follow-up. This will 
be modelled using a random effect logistic regression model. The model will include treatment group, 
baseline HbA1c and centre. Treatment effect will be reported and presented as Odds Ratio (OR) with 
its associated 95% CI and p-value. 
 
5.6.4    Model Checking 
Frequency graphs and the ratio of the variance to the mean will be used to assess the distribution of 
severe hypoglycaemia episodes. Failure to properly address existing over dispersion leads to serious 
underestimation of standard errors and misleading inference for the treatment effect.  The Deviance 
and Likelihood Ratio Test (LRT) will be employed to assess goodness of fit of the Poisson linear 
regression model against two specific alternatives: a) a zero-inflated Poisson GLM (in the case of 
overdispersion due to excess zeros, or participants who experienced no episodes), and b) negative 
binomial regression for more general overdispersion. Further model diagnostics including measures 
of influence such as Cook’s Distance will be undertaken for sensitivity analysis.  
 
Unlike linear regression where graphical diagnostic displays can be very useful, for logistic regression 
models, the discreteness of binary data makes it difficult to interpret such displays. Three methods 
will be used for diagnostic checking of logistic regression models. Local mean deviance plots for 
detecting overall lack of fit, empirical probability plots to point out isolated departures from the fitted 
model and partial residual plots (smoothed) to identify specific causes of lack of fit.   
 
5.7 Analysis of Secondary Outcomes - Psychological 
All psychological outcomes will be analysed by the team at the University of Surrey, led by Debbie 
Cooke. The planned analysis will be defined by the team in a separate document and will be discussed 
with the statistical team to ensure consistency between methods. This will be signed off prior to data 
analysis.  
 
5.8 Safety Outcomes  
Adverse Events (AE) will be recorded throughout the trial and are defined as any unwanted medical 
occurrences which includes any episodes of diabetic ketoacidosis and any increase in frequency of 
severe hypoglycaemia. Serious Adverse Event (SAE) will also be recorded throughout the trial and are 
defined as AEs which result in hospitalisation or have a risk to life. A detailed description of AEs and 
SAEs can be found in the protocol. 
 
Summary measures will be presented by treatment group as the number and percentage of 
participants reporting an AE/SAE as well as the total number of AE/SAEs reported and will be on an 
ITT basis. No formal statistical testing will be undertaken.  
 
5.9 Statistical Software  
This analysis will be carried out using any suitable packages such as R or STATA. 
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